US Pat. No. 10,456,345

FURTHER PREPARATIONS OF SILK PROTEINS, SEED OILS, MONOSACCHARIDE, NATURAL BOTANICALS AND POLYSACCHARIDE MIXTURES IN COMPOSITIONS FOR HAIR CARE OR HAIR REPAIR, AND SKIN CARE AND TOPICAL TREATMENTS

Valerie M. Ross, San Die...

1. A topical composition comprising: sericin; chitosan; and ribose; wherein the sericin, chitosan, and ribose are part of a first phase comprising water, and wherein the topical composition comprises a water-in-oil emulsion formed from the first phase and a second phase comprising at least one seed oil.
US Pat. No. 10,457,884

MIXED DETERGENT COMPOSITION FOR INTAKE VALVE DEPOSIT CONTROL

Afton Chemical Corporatio...

1. A detergent additive package for an unleaded gasoline fuel comprising a Mannich base detergent mixture, wherein the mixture comprises a first Mannich base detergent component having a tertiary amino group and derived from an aliphatic linear, branched, or cyclic diamine having one primary or secondary amine group and one tertiary amino group in the molecule and a second Mannich base detergent component derived from a monoamine, wherein a weight ratio of the first Mannich base detergent to the second Mannich base detergent in the mixture ranges from about 1:6 to about 3:1.
US Pat. No. 10,455,833

METHODS OF RAPIDLY PREVENTING THE SPREAD OF AVIAN INFLUENZA VIRUS IN POULTRY FLOCKS

AGRO INNOVATION INTERNATI...

1. A method of rapidly inactivating Avian Influenza Virus (AIV) in the housing of a poultry flock in need thereof, comprising:applying a powdered composition to the floor of said housing in amounts effective to rapidly inactivate AIV, said floor of said poultry housing comprising bedding material, said composition comprising (i) salicylic acid in an amount ranging from about 1 wt % to about 5 wt %; and (ii) aluminum sulfate in an amount ranging from about 5 wt % to about 15 wt % and calcium sulfate in an amount ranging from about 80 wt % to about 90 wt %, wherein said inactivation of AIV occurs within about ten to fifteen minutes after application of said composition, and wherein said AIV is a low pathogenic strain.
US Pat. No. 10,456,346

COSMETIC FORMULATIONS FOR TOPICAL APPLICATIONS CONTAINING ERYTHROPOIETIN-DERIVED MOLECULES

ASC REGENITY LTD., Londo...

1. A cosmetic formulation or composition for topical administration of the skin, for skin repair, rejuvenation of skin, natural skin glow, reduction of wrinkles, anti-aging of skin, and avoidance and improvement of dry and ruptured skin, the formulation or composition comprising:(i) at least one isolated tissue-protective polypeptide (tpP) consisting of 11 to 40 amino acids, wherein the tissue-protective polypeptide is an agonist of the EPO receptor (EpoR) and/or the common receptor (ßcR), targets CD90 expressing skin cells, and does not or not essentially elicit hematopoietic/erythropoietic activity, and is an EPO peptide variant, wherein the EPO variant comprises or is one of the amino acid sequences selected from the group consisting of:
NEQLERALNTS (SEQ ID NO: 12);
NEQLERALNST (SEQ ID NO: 13);
QDQLERALNTS (SEQ ID NO: 14);
QDQLERALNST (SEQ ID NO: 15), and
(ii) a lipid compound, a composition of lipid compounds, or a lipid structure, wherein the tissue-protective polypeptide (tpP) is linked or associated to the lipid compound or lipid structure by ionic interaction or by covalent bonding, or is admixed therewith or embedded or encapsulated therein by forming a micelle or liposomal structure, and
(iii) at least one triggering agent that stimulates vasculature relaxation and/or supports transport of the tissue-protective polypeptide (tpP) to the CD90 expressing skin cells, wherein the triggering agent stimulates nitric oxide (NO) and/or acetylcholine formation in the CD90 expressing skin cells.
US Pat. No. 10,457,629

THERAPEUTIC DNP DERIVATIVES AND METHODS USING SAME

Yale University, New Hav...

1. A method of ameliorating a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of hypertriglyceridemia, fatty liver, and insulin resistance, the method comprising administering to the subject a therapeutically effective amount of 2,4-dinitrophenyl methyl ether or a solvate thereof.
US Pat. No. 10,456,347

COMPOSITION FOR INJECTION OF HYALURONIC ACID, CONTAINING HYALURONIC ACID DERIVATIVE AND DNA FRACTION, AND USE THEREOF

BMI KOREA CO., LTD, Jeju...

1. A method for repair or replacement of biological tissue, filling wrinkle, remodeling of the face or increasing lip volume, skin rehydration by mesotherapy, replacement or supplement of joint synovial fluid or treating dry eye syndrome, comprising administering to the subject an effective amount of an injectable hyaluronic acid composition comprising hyaluronic acid derivatives having the degree of crosslinking of 0.1 to 200% wherein the concentration of the hyaluronic acid derivative is 1 to 50 mg/ml and DNA fractions of 0.1 to 50 wt % based on the total composition.
US Pat. No. 10,458,911

METHOD FOR SEARCHING CANDIDATE MATERIAL FOR ANTI-CANCER DRUG USING LOCALIZED SURFACE PLASMON RESONANCE

KOREA UNIVERSITY RESEARCH...

1. A method for screening an anticancer candidate, comprising:immobilizing gold nanoparticles onto a substrate;
forming a STAT3 protein conjugate by binding a STAT3 protein involved in carcinogenesis and metastasis to the immobilized gold nanoparticles, recording a spectrum of the protein conjugate as the STAT3 protein is undergoing a phosphorylation or a dimerization step without the presence of the candidate, and analyzing the spectrum of the STAT3 protein conjugate to obtain reference data;
forming a mixture by adding a candidate inhibiting the activity of the STAT3 protein to the STAT3 protein conjugate, recording a spectrum of the mixture as the STAT3 protein is undergoing a phosphorylation or a dimerization, and analyzing the spectrum of the mixture to obtain comparative data; and
comparing the reference data with the comparative data to determine whether the candidate inhibits the activity of the protein,
wherein the addition of the candidate inhibiting the activity of the protein induces changes in the phosphorylation and dimerization of the STAT3 protein and the binding profile of the STAT3 protein with the gold nanoparticles on the substrate.
US Pat. No. 10,456,348

AGENT AND METHOD FOR THE TEMPORARY DEFORMATION OF KERATIN-CONTAINING FIBERS

10. A method for the temporary deformation of keratin-containing fibers, in which the keratinic fibers are acted upon by a cosmetic composition according to claim 1 and temporarily fixed in their shape.
US Pat. No. 10,457,887

TRUNK PISTON ENGINE OIL COMPOSITION

CHEVRON ORONITE TECHNOLOG...

1. A low sulfur marine distillate fuel trunk piston diesel engine lubricating oil composition comprising:(a) a major amount of a Group I base oil or a Group II base oil or mixtures thereof;
(b) at least one or more detergents comprising at least one overbased salt of an alkyl-substituted hydroxybenzoic acid; and
(c) a succinimide dispersant derived from polyalkylene having a number average molecular weight (Mn) of 1400-3000;
wherein the alkyl groups of the overbased salt of an alkyl-substituted hydroxybenzoic acid, are at least 90 mole % C20 or greater; and wherein the succinimide dispersant is present at greater than 1.2 wt. % on an actives basis; and the TBN of the low sulfur marine distillate fuel trunk piston diesel engine lubrication oil composition is less than 30 mg KOH/g.
US Pat. No. 10,457,888

LUBRICATING MEMBERS FOR RAZOR CARTRIDGES

Braun GMBH, Kronberg (DE...

1. A razor cartridge comprising:a) a razor cartridge housing containing at least one blade;
b) a guard member positioned on the razor cartridge housing forward of the at least one blade;
c) a cap positioned on the razor cartridge housing aft of the at least one blade, wherein during a shaving stroke skin is contacted by the guard prior to the at least one blade, and the at least one blade prior to contacting the cap; said cap comprising at least one lubricating member, each lubricating member comprising:
i) from about 25% to about 65% by weight of said lubricating member of a lipophilic structurant or mixture thereof, wherein said lipophilic structurant is selected from C14-C20 alcohols, microcrystalline wax, stearyloxytrimethylsilane, and mixtures thereof,
ii) from about 20% to about 60% by weight of said lubricating member of a silicone polyether block copolymer, wherein said silicone polyether block copolymer consists essentially of repeating units of polyethylene oxide, silicone, and polypropylene oxide, at levels of: about 1% to about 50%, by weight of polyethylene oxide, from about 20% to about 90% by weight of polypropylene oxide and from about 1% to about 20% by weight of silicone, and has a ratio of polyethylene oxide units to polypropylene oxide units to silicone units of from 20:65:15, and
iii) from about 20% to about 40% by weight of said lubricating member of a liquid phase, wherein said liquid phase comprises a component selected from natural oil, synthetic oil, natural butter, triglyceride, petrolatum, silicone, and mixtures thereof;
iv) wherein said silicone polyether block copolymer is free of any additional alkyl chains; and
v) wherein said lubricating member is substantially free of soap.
US Pat. No. 10,455,837

COMPLEXES OF CLOQUINTOCET AND AMINE-CONTAINING POLYMERS OR OLIGOMERS

Dow ArgoSciences LLC, In...

1. A composition comprising a safener complex and a pesticide, wherein:the safener complex comprises cloquintocet acid, or a salt thereof, and an amine-containing polymer or oligomer;
the weight ratio of the cloquintocet acid, or salt thereof, to the amine-containing polymer or oligomer ranges from 1:2 to 10:1; and
the amine-containing polymer or oligomer includes a branched, spherical polyethyleneimine.
US Pat. No. 10,456,350

EYE MAKE-UP COSMETIC COMPOSITION WITH EXCELLENT CURLING HOLDING FORCE

AMOREPACIFIC CORPORATION,...

1. A cosmetic composition for eye makeup, which comprises low-specific gravity volatile oil and low-specific gravity powder, and a dispersant,wherein the low-specific gravity volatile oil comprises low-specific gravity hydrocarbon oil and low-specific gravity volatile silicone oil,
wherein a specific gravity of the low-specific gravity hydrocarbon oil is equal to or more than 0.1 and equal to or less than 0.8, and a specific gravity of the low-specific gravity silicone oil is equal to or more than 0.1 and equal to or less than 0.85, and the specific gravity of the low-specific gravity powder is equal to or more than 0.001 and less than 1, when the specific gravity of the standard material, pure water at 4° C., is taken as 1, wherein the composition is a non-aqueous composition not comprising water or aqueous ingredients.
US Pat. No. 10,456,606

DECOLORIZATION OF COLORED KERATINIC FIBERS

1. A multi-component packaging unit (kit of parts) for the reductive decolorization of colored keratinic fibers comprising, packaged separately from one another,(I) a container (A) containing a cosmetic agent (a),
(II) a container (B) containing a cosmetic agent (b), and
(III) a container (C) containing a cosmetic, aqueous agent (c), with
the agent (a) in container (A) comprising 85.0 to 100 wt % with respect to the total weight of agent (a), of
(a1) one or more reducing agents selected from the group consisting of sodium dithionite, zinc dithionite, potassium dithionite, sodium sulfite, sodium hydrogen sulfite, potassium sulfite, potassium hydrogen sulfite, ammonium sulfite, sodium thiosulfate, potassium thiosulfate, ammonium thiosulfate, hydroxymethane sulfinic acid, aminomethane sulfinic acid, cysteine, thiolactic acid, sulfanylacetic acid (thioglycolic acid), ascorbic acid, and mixtures thereof,
the agent (b) in container (B), comprises
(b1) water and
(b2) one or more acids selected from inorganic and/or organic acids, and
agent (c) in container (C) comprising
(c1) one or more acids selected from the group consisting of malonic acid, oxalic acid, and mixtures thereof, and
(c2) methanesulfonic acid, wherein the total amount of the one or more acids (c1) and the methanesulfonic acid (c2) is present in agent (c) in a total quantity of 2.0 to 20.0 wt % with respect to the total weight of agent (c) and
(c3) one or more zwitterionic and/or amphoteric surfactantswhereinthe agent (a) in container (A) is a water-free agent,
the agent (b) in container (B) is an aqueous agent having a pH of 1 to 6, measured using a Schott N61-type glass electrode at a temperature of 22° C.,
and
the agent (c) in container (C) has a pH of 0.5 to 4.0 measured using a Schott N61-type glass electrode at a temperature of 22° C.
US Pat. No. 10,456,607

PHOTOACTIVE GRAFTED POLYSACCHARIDE AND USE THEREOF IN COSMETICS

1. A polysaccharide polymer grafted with photoactive groups of an azide or diazirine of formula (I):PS—(O—CO-L-X)a(OH)b  (I)
in which PS denotes the basic backbone of the polysaccharide bearing the hydroxyl groups;
L is a linear, branched or cyclic, saturated or unsaturated divalent hydrocarbon-based group comprising from 1 to 20 carbon atoms, which may be interrupted with one or more non-adjacent heteroatoms chosen from sulfur, oxygen, or —NH—, —COO—, —CONH—, —O—CO—NH— or —NH—CO—NH— groups, said divalent group optionally substituted with one or more groups chosen from hydroxyl, amine, thiol, carboxylic acid, amide, cyano, and acyl (C1-C4)amino groups;
X denotes the azide or diazirine photoactive group;
a denotes the content of OH groups substituted with the photoactive group;
b denotes the content of unsubstituted free OH groups;
a being between 0.02 and 0.5; b being between 0.5 and 0.98;
and a+b=1;
with the exception of compounds (I) for which:
PS is dextran and -L-X=—(CH2)5—N3
PS is hyaluronic acid and -L-X=—(CH2)3—N3.
US Pat. No. 10,457,890

PHOSPHOLIPASE C

DSM IP ASSETS B.V., Heer...

1. A process for hydrolysing one or more phospholipids comprising:a) separating the one or more phospholipids from an oil;
b) incubating the one or more phospholipids with a polypeptide having phospholipase C activity selected from the group consisting of:
i) a polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 2;
ii) a polypeptide that has at least 85% sequence identity to the mature polypeptide sequence of SEQ ID NO: 2; and
iii) a polypeptide encoded by a nucleic acid that has at least 85% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 1,
wherein the one or more phospholipids are hydrolysed.
US Pat. No. 10,455,839

PRE-PLANT BIOCIDE USES OF AQUEOUS CYANAMIDES

METBRO DISTRIBUTING LP, ...

1. A method for using a pre-plant biocide to prepare a cultivation medium for growing a plant, the method comprising:i) irrigating an unplanted cultivation medium to a greater than 50% water saturation level;
ii) after the irrigating, allowing the irrigated cultivation medium to drain to a saturation level of 50%-25%; and
iii) contacting the cultivation medium with the pre-plant biocide comprising water and hydrogen cyanamide at a concentration of 600-10,000 ppm, thereby uniformly applying the pre-plant biocide, wherein the contacting is performed 30 to 90 days prior to a time of planting the plant;
and wherein:
(a) the applying the pre-plant biocide reduces a number of viable pathogenic nematodes in the root zone of the cultivation medium by at least about 90% to a depth of 4 feet at the time of planting relative to an untreated control cultivation medium;
(b) the applying the pre-plant biocide reduces a number of viable weeds in the cultivation medium by at least about 99% at the time of planting relative to an untreated control cultivation medium; or
(c) the applying the pre-plant biocide reduces a number of viable pathogenic fungal organisms in the cultivation medium by at least about 90% at the time of planting relative to an untreated control cultivation medium.
US Pat. No. 10,456,352

OXIDATION DYEING AGENT WITH SPECIAL HYDROXY-TERMINATED, AMINE-FUNCTIONALIZED SILICONE POLYMERS

1. Cosmetic agent for coloring keratin fibers, comprising in a cosmetically tolerant carriera) at least one chromophoric compound, selected from the group of oxidative dye precursors, partially-oxidative dyes and the mixtures thereof,
b) at least one hydroxy-terminated amine-functionalized silicone polymer of formula (I)
(O1/2H)t[A]a  (I)
where A=(SiO4/2)k(R1SiO3/2)m(R12SiO2/2)p(R13SiO1/2)q(O2/2SiR1—(CH2)x—B—(CH2)y—NH2)s(O1/2SiR1R2—(CH2)x—B—(CH2)y—NH2)r
wherein
the at least one hydroxy-terminated amine-functionalized silicone polymer of formula (I) is terminated at a first end with a hydroxy group and is terminated at a second end with an amine group,
a denotes integers from 1 to 20,000, wherein, if a ?2, the respective values k, m, p, q, s and r in a structural element A can be selected irrespective of previous structural elements A,
R1 and R2 denote, independently of one another, hydrogen, a OH group, a linear or branched C1-C12-alkyl group, a phenyl group or a vinyl group,
B denotes an oxygen atom, a NH group or sulfur,
x and y denote, independently of one another, integers from 1 to about 10,
t denotes integers from 1 to 5, and
the total of k+m+p+q+s+r denotes integers from 3 to about 20,000.
US Pat. No. 10,458,916

RAPID TESTS FOR THE DETECTION OF INHIBITORS OF ENZYMES AND HUMAN EXPOSURE TO THE SAME

ANP Technologies, Inc., ...

1. A system for detecting presence of an inhibitor of an esterase comprising:a) a self-calibrated, modular, handheld device comprising a top piece and a bottom piece, said bottom piece comprising a negative control reaction zone and a test reaction zone for a test sample suspected of comprising an inhibitor of an esterase; each reaction zone comprising a porous matrix consisting essentially of an immobilized substrate of said esterase, each reaction zone positioned below an opening in said top piece when said top piece is assembled on said bottom piece; and said negative control reaction zone and said test reaction zone are separate and exclusive; wherein in a reaction of said substrate and said esterase, a product of said reaction comprises a detectable reporter; and wherein a negative control reaction zone comprising a negative control sample comprises detectable reporter; and
b) separate from said device, two reaction containers, each container comprising a same amount of said esterase, and optionally,
c) separate from said device, a reader that detects said detectable reporter.
US Pat. No. 10,457,636

PRODUCTION METHOD OF ?-CAPROLACTAM

Sumitomo Chemical Company...

1. A production method of ?-caprolactam, comprising a step of Beckmann-rearranging cyclohexanone oxime in a gas phase in the presence of a zeolite catalyst containing a silicon element and at least one element selected from the group consisting of alkaline earth metal elements and a magnesium element, wherein the concentration of the at least one element selected from the group consisting of alkaline earth metal elements and a magnesium element in the zeolite catalyst is 3 ppm by mass or more and 10000 ppm by mass or less.
US Pat. No. 10,456,354

READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE

SLAYBACK PHARMA LLC, Pri...

1. A ready-to-use injectable pharmaceutical composition comprising (i) neostigmine or a pharmaceutically acceptable salt, solvate or hydrate thereof, (ii) glycopyrrolate or a pharmaceutically acceptable salt, solvate or hydrate thereof, (iii) one or more aminopolycarboxylic acids, and (iv) a pharmaceutically acceptable liquid vehicle, wherein the pharmaceutical composition is stable for at least 3 months at 25° C. and 60% relative humidity.
US Pat. No. 10,457,893

PROCESS OF WASHING FABRICS THAT HAVE A SOFTENING ACTIVE DEPOSITED THEREON

1. A process of washing a fabric, comprising the steps of:a. obtaining a fabric comprising a softening active deposited thereon, wherein the softening active comprises a quaternary ammonium ester fabric softening active;
b. treating the fabric in a wash step, wherein the wash step comprises contacting the fabric with a wash liquor;wherein the wash liquor is prepared by diluting a liquid laundry detergent composition, wherein the liquid laundry detergent composition is comprised in a water-soluble unit dose article comprising a water-soluble film, in water by between about 300 and about 800 fold andwherein the liquid laundry detergent composition comprises between about 0.02% and about 2% by weight of the liquid laundry detergent of a fatty alcohol ethoxylate non-ionic surfactant, wherein the fatty alcohol ethoxylate non-ionic surfactant comprises on average between about 12 and about 15 carbons in the alcohol carbon chain, and on average between about 7 and about 8 ethoxy units in the ethoxylation chain; and
between about 20% and about 45% by weight of the liquid laundry detergent composition of non-soap anionic surfactant, wherein the non-soap anionic surfactant comprises linear alkylbenzene sulphonate and alkoxylated alkyl sulphate, and where the weight ratio of linear alkylbenzene sulphonate to alkoxylated alkyl sulphate is between about 2:1 and 1:1,
wherein the weight ratio of non-soap anionic surfactant to fatty alcohol ethoxylate non-ionic surfactant is from about 5:1 to about 23:1,
wherein the weight ratio of linear alkylbenzene sulphonate to fatty alcohol ethoxylate non-ionic surfactant is between about 2:1 to about 20:1,
wherein the weight ratio of alkoxylated alkyl sulphate to fatty alcohol ethoxylate non-ionic surfactant is between about 2:1 and about 20:1,
wherein the liquid laundry detergent composition comprises between about 0.5% and about 15% by weight of the liquid laundry detergent composition of water, and wherein the liquid laundry detergent composition comprises a polymer selected from the group consisting of alkoxylated polyethyleneimine, alkoxylated polyalkyl phenol, an amphiphilic graft copolymer, a polyester terephthalate, hydroxyethylcellulose, a carboxymethylcellulose, and mixtures thereof.
US Pat. No. 10,456,355

PHARMACEUTICAL HYDROCORTISONE SOLUTION FOR AN INJECTION DEVICE

CROSSJECT, Dijon (FR)

1. A pharmaceutical hydrocortisone solution which comprises at least:hydrocortisone or a pharmaceutically-acceptable salt thereof;
rongalite;
disodium ethylenediaminetetraacetic acid (disodium EDTA);
a solvent.
US Pat. No. 10,457,894

COLOR-PROTECTING DETERGENT OR CLEANING AGENT HAVING AN OPTICAL BRIGHTENER

1. A water-soluble packaging having at least two chambers and containing a first liquid detergent or cleaning agent with a low content of water, a second liquid detergent or cleaning agent with a low content of water and a water-soluble wrapping, said first liquid detergent or cleaning agent with a low content of water containing an optical brightener and said second liquid detergent or cleaning agent with a low content of water containing a color transfer inhibitor, wherein low content of water is less than 15% by weight in each case in relation to the total first and/or second liquid detergent or cleaning agent; and wherein the first liquid detergent or cleaning agent is free from color transfer inhibitors and the second liquid detergent or cleaning agent is free from optical brighteners.
US Pat. No. 10,456,356

USE OF ENCAPSULATED CELL THERAPY FOR TREATMENT OF OPHTHALMIC DISORDERS

Neurotech USA, Inc., Cum...

1. A method of improving optic nerve regeneration; preserving or improving the ganglion cell complex, the thickness of the outer retinal layer, or both the ganglion cell complex and the thickness of the outer retinal layer; or preserving or improving the retinal fiber layer in a patient in need thereof comprising: implanting into an eye of the patient a biocompatible capsule comprisinga) a core comprising 0.5-1×106 ARPE-19 cells that are genetically engineered to secrete a therapeutically effective amount of CNTF upon implantation, wherein the therapeutically effective amount is between 0.1 and 20 ng/day;
b) a semi-permeable membrane surrounding the core, wherein the membrane has a molecular weight cut off of 50 kD, permits the diffusion of the CNTF therethrough, and is between 90 and 120 ?m thick; and
c) a matrix disposed within the semi-permeable membrane, wherein said matrix comprises monofilaments that are twisted into a yarn that is in non-woven strands, wherein the cells are distributed thereon, and wherein the monofilaments comprise polyethylene terephthalate (PET) fibers that comprise 40-85% of the internal volume of the capsule;
wherein said biocompatible capsule produces 0.6-5.0 ng/day of CNTF for at least 12 months post implantation, and
wherein the capsule is configured as a hollow fiber having an internal diameter of 0.9-1.2 mm and a length of 4-11 mm.
US Pat. No. 10,456,357

ORALLY ADMINISTRABLE FORMULATION

1. An aqueous-based oral liquid formulation comprising a solvent comprising water, alcohol and propylene glycol and/or polyethylene glycol in an amount in the range of about 60-99% by wt, wherein the formulation comprises up to 40% by wt water, up to 65% by wt alcohol and up to 50% by wt propylene glycol and/or polyethylene glycol combined with pharmaceutical agent-containing particles of plant material in an amount in the range of about 1-40% by wt, wherein the pharmaceutical agent is selected from the group consisting of cannabinoids, cannabinoid derivatives, terpenes and mixtures thereof, and at least 50% by wt of the particles range in size from about 50 to about 2000 ?m.
US Pat. No. 10,457,896

DRY AND PORTABLE SPOT REMOVAL PRODUCT AND METHOD COMPRISING AN ALUMINUM DIOCTAHEDRAL PHYLLOSILICATE

Spot Stuff, Inc., Minnet...

1. A method of removing a grease or oil based stain from a substrate consisting essentially of applying a dry and portable stain removal formulation comprising a silica and alumina tetrahedral (zeolite) mineral and an aluminum dioctahedral phyllosilicates mineral, said aluminum dioctahedral phyllosilicates mineral being preheated at least for one hour and between 600 and 1,200° F.
US Pat. No. 10,455,845

DAIRY COMPOSITIONS AND METHOD OF MAKING

fairlife, LLC, Chicago, ...

1. A method for making a dairy composition, the method comprising:subjecting milk to an ultrafiltration step to produce a UF permeate fraction and a UF retentate fraction;
subjecting the UF permeate fraction to a nanofiltration step to produce a NF permeate fraction and a NF retentate fraction;
combining the UF retentate fraction with the NF permeate fraction to form a mixture;
subjecting the mixture to a diafiltration step to produce a DF permeate fraction and a DF retentate fraction;
combining the DF retentate fraction with the NF retentate fraction to form a blended composition; and
treating the blended composition with lactase enzyme to form a dairy composition having a lactose content of 0.1 to 1 wt. %.
US Pat. No. 10,456,358

ISOXAZOLINE COMPOSITIONS AND USE THEREOF IN THE PREVENTION OR TREATMENT OF PARASITE INFESTATIONS IN ANIMALS

Intervet Inc., Madison, ...

1. A method of preventing or treating parasite infestations in animals by administering to such animal in its drinking water a pharmaceutical composition consisting essentially of fluralaner or a salt or solvate thereof, and a pharmaceutically acceptable carrier consisting essentially of ethyl lactate, diethylene glycol monoethyl ether and a polysorbate surfactant.
US Pat. No. 10,456,870

METHOD FOR PRODUCING A SOLDERED CONNECTION

1. A method for making a firmly-bonded connection of an electronic component to a substrate, comprisinga) providing an electronic component having a first surface to be connected and a substrate having a second surface to be connected;
b) applying a copper paste onto at least one of the surfaces to be connected and drying the layer of copper paste;
c1) applying a solder agent onto the dried layer of copper paste and arranging the electronic component and the substrate such that the first surface of the electronic component to be connected and the second surface of the substrate to be connected contact each other by the two-layer combination of dried copper paste and solder agent;
or
c2) arranging the electronic component and the substrate such that the first surface of the electronic component to be connected and the second surface of the substrate to be connected contact each other by the dried copper paste, and applying a solder agent next to the layer of dried copper paste; and
d) soldering the arrangement produced in c1) or c2) to generate a firmly-bonded connection between the electronic component and the substrate;
wherein step c1) or step c2) directly follows step b) with no intervening step; and
wherein the copper paste contains (i) 66-98% by weight of a first type of particles each comprising a phosphorus fraction of >0 to ?500 wt-ppm and selected from the group consisting of copper particles, copper-rich copper/zinc alloy particles, and copper-rich copper/tin alloy particles, ii) 1-20% by weight of a second type of particles selected from the group consisting of tin particles, tin-rich tin/copper alloy particles, tin-rich tin/silver alloy particles, and tin-rich tin/copper/silver alloy particles, wherein the second type of particles contain no phosphorus, and (iii) 1-20 percent by weight vehicle, wherein the mean particle diameter of metallic particles (i) and (ii) is ?15 ?m.
US Pat. No. 10,457,897

LIQUID LAUNDRY DETERGENT COMPOSITION COMPRISING A FIRST POLYMER AND A SECOND POLYMER

1. A liquid laundry detergent composition comprising:a. between about 5% and about 35% by weight of the liquid laundry detergent composition of an amine neutralised C12-14 linear alkylbenzene sulphonate;
b. between about 0.05% and about 3% by weight of the liquid laundry detergent composition of a first polymer, wherein the first polymer is a cationically modified polysaccharide;
c. between about 0.05% and about 3% by weight of the liquid laundry detergent composition of a second polymer, wherein the second polymer is a cellulosic polymer that is a hydrophobically modified carboxymethylcellulose having a degree of substitution (DS) of from about 0.01 to about 0.99 and a degree of blockiness (DB) such that either DS+DB is at least about 1.00 and/or DB+2DS?DS2 is at least about 1.20.
US Pat. No. 10,455,846

DAIRY COMPOSITIONS AND METHOD OF MAKING

fairlife, LLC, Chicago, ...

1. A method for making a dairy composition, the method comprising:subjecting milk to an ultrafiltration step to produce a UF permeate fraction and a UF retentate fraction;
subjecting the UF permeate fraction to a nanofiltration step to produce a NF permeate fraction and a NF retentate fraction;
subjecting the NF permeate to a reverse osmosis step to produce a RO permeate fraction and a RO retentate fraction;
combining the UF retentate fraction with at least one of water or the RO permeate fraction to form a mixture;
subjecting the mixture to a diafiltration step to produce a DF permeate fraction and a DF retentate fraction;
combining the DF retentate fraction with the NF retentate fraction and the RO retentate fraction to form a blended composition; and
treating the blended composition with lactase enzyme to form a dairy composition having a lactose content of 0.1 to 1 wt. %.
US Pat. No. 10,456,359

SYNERGISTIC BEVERAGE COMPOSITION

Harsha Chigurupati, Hyde...

1. A beverage composition comprising:(a) a saponin glycoside in a mass concentration range of 0.01% to 0.5%, wherein the saponin glycoside comprises Glycyrrhizin (GA), Glycyrrhizin (GA) salt, or a combination thereof, and
wherein the Glycyrrhizin (GA) comprises 18-?-Glycyrrhizin, 18-?-Glycyrrhizin, or a combination thereof;
(b) an Amino-Acid or Amino-Acid derivative in a mass concentration range of 0.04% to 3.0%, wherein Amino-Acid derivative is selected from the group consisting of a dipeptide, a tripeptide, an oligopeptide, a protein, and a protein hydrolysate; and
(c) a sugar or sugar alcohol or combination thereof in a mass concentration range of 0.5% to 3.0%, wherein the sugar is selected from the group consisting of D-Maltodextrin, L-Maltodextrin, D-Maltose, L-Maltose, D-Dextrose, L-Dextrose, D-Glucose, L-Glucose, D-Trehalose, L-Trehalose, D-Sucrose, L-Sucrose, D-Lactose, L-Lactose, Hydrogenated Starch Hydrolysates, D-Fructose and D-Galactose, or a mixture thereof; and
wherein the sugar alcohol selected from the group consisting of D-Glycerol, L-Glycerol, D-Mannitol, L-Mannitol, D-erythritol, L-erythritol, D-xylitol, or L-xylitol, L-Maltitol, D-Maltitol, L-Sorbitol, D-Sorbitol, L-Lactitol, D-Lactitol, L-Isomalt and D-Isomalt, and mixtures thereof.
US Pat. No. 10,456,871

SOLDER PASTE

1. A solder paste comprising (i) 10-30% by weight of at least one type of particles each comprising a phosphorus fraction of >0 to ?500 wt-ppm and selected from the group consisting of copper particles, copper-rich copper/zinc alloy particles, and copper-rich copper/tin alloy particles, (ii) 60-80% by weight of at least one type of particles containing no phosphorus and selected from the group consisting of tin particles, tin-rich tin/copper alloy particles, tin-rich tin/silver alloy particles, and tin-rich tin/copper/silver alloy particles, and (iii) 3-30% by weight solder flux, wherein the mean particle diameter of metallic particles (i) and (ii) is ?15 ?m.
US Pat. No. 10,457,898

LIQUID DETERGENT COMPOSITION COMPRISING CELLULOSIC POLYMERS AND CELLULASE

1. A liquid laundry detergent composition comprising:a. between about 0.0001% and about 0.1% by weight of the liquid laundry detergent composition of a cellulase;
b. between about 0.05% and about 3% by weight of the liquid laundry detergent composition of a first cellulosic polymer, wherein the first cellulosic polymer is a cationically modified cellulosic polymer;
c. between about 0.05% and about 3% by weight of the liquid laundry detergent composition of a second cellulosic polymer wherein the second cellulosic polymer is a hydrophobically modified carboxymethyl cellulose having a degree of substitution (DS) of from about 0.01 to about 0.99 and a degree of blockiness (DB) such that either DS+DB is of at least about 1.00 and/or DB+2DS-DS2 is at least about 1.20.
US Pat. No. 10,461,228

LED PACKAGING MATERIAL AND MANUFACTURING METHOD OF THE SAME

Shenzhen China Star Optoe...

1. A method for manufacturing a light-emitting diode (LED) packaging material, comprising the following steps:mixing graphene with a curing agent at a predetermined ratio to form a first mixed solution including a mixture of graphene and the curing agent;
providing epoxy resin and an accelerating agent with a predetermined ratio, and adding the epoxy resin and the accelerating agent into the first mixed solution of graphene and the curing agent to form a second mixed solution, which comprises the mixture of graphene and the curing agent that is added with epoxy resin and the accelerating agent; and
subjecting the second mixed solution to an ultrasonic process to form a material of a fully-mixed combination of graphene and epoxy resin,
wherein the first mixed solution is formed by mixing graphene and the curing agent before epoxy resin is added in the first mixed solution.
US Pat. No. 10,455,847

CONFECTIONARY PRODUCTS WITH CALCIUM PHOSPHATE

Perfetti Van Melle S.p.A....

1. A method of treating dentinal sensitivity in a subject in need thereof, said method comprising:administering to said subject a confectionary product free from acids and comprising calcium phosphate, wherein said calcium phosphate consists of from 0.7% to 18% by weight of dibasic calcium phosphate and from 0.07% to 3.6% by weight of tribasic calcium phosphate.
US Pat. No. 10,457,899

POLYFUNCTIONAL POLYMERS BASED ON PHOSPHONATE UNITS AND AMINE UNITS

RHODIA OPERATIONS, Paris...

1. A polyfunctional polymer comprising:monomer units u1 bearing phosphonic acid functions —P(?O)(OH)2 in acid form or, totally or partly, in deprotonated form;
monomer units u2 bearing amine functions, wherein the amine functions of the monomer units u2 comprise primary amines —NH2 that are optionally totally or partly protonated in ammonium form NH3+;
optionally, monomer units u3 bearing alcohol functions —OH.
US Pat. No. 10,460,973

ADHESIVE TAPE FOR SEMICONDUCTOR PROCESSING AND METHOD FOR PRODUCING SEMICONDUCTOR DEVICE

LINTEC CORPORATION, Itab...

1. A method for producing a semiconductor device, comprising:sticking a pressure sensitive adhesive tape on a front face of a semiconductor wafer;
forming a groove from the front face of the semiconductor wafer, or forming a modified region in an inside of the semiconductor wafer from the front face ora back face of the semiconductor wafer;
grinding the semiconductor wafer on which the pressure sensitive adhesive tape is stuck on the front face thereof, and the groove or modified region is formed, from the back face side to cingulate the semiconductor wafer into plural chips starting from the groove or modified region; and
releasing the pressure sensitive adhesive tape from the plural chips,
wherein the pressure sensitive adhesive tape comprises:
a base,
a buffer layer provided on one face of the base, and
a pressure sensitive adhesive layer provided on the other face of the base,
wherein the pressure sensitive adhesive tape has a ratio of a thickness of the buffer layer to a thickness of the base of 0.7 or less and an indentation depth of a front face on the buffer layer side of 2.5 ?m or less.
US Pat. No. 10,456,361

RAPIDLY DEGRADING EMBOLIC PARTICLES WITH THERAPEUTIC AGENT RELEASE

Boston Scientific Scimed,...

1. An embolic particle comprising sub-particles dispersed in a matrix that comprises a biodegradable polymer,wherein the sub-particles comprise a therapeutic agent of low solubility,
(a) wherein said sub-particles comprise elongate particles having an aspect ratio ranging from 10:1 to 1000:1 that comprise said therapeutic agent and/or (b) wherein said sub-particles comprise particles that comprise an anti-tumor agent dispersed in oil,
wherein upon administration to a blood vessel, the matrix of the embolic particle biodegrades and the sub-particles remain localized in the blood vessel such that they continue to release therapeutic agent locally in the blood vessel after the matrix has completely degraded, and
wherein said sub-particles comprise said elongate particles having an aspect ratio ranging from 10:1 to 1000:1 that comprise said therapeutic agent.
US Pat. No. 10,457,900

DETERGENT COMPOSITION COMPRISING AN ALKYL ETHER SULFATE-RICH SURFACTANT SYSTEM AND COATED ENCAPSULATES

1. A liquid detergent composition comprising:A) from about 15% to about 60%, by weight of the detergent composition, of a surfactant system, wherein the surfactant system comprises:
a) an anionic alkoxylated alkyl sulphate surfactant present at a level of about 90% to 100%, by weight of the surfactant system;
b) up to 5% by weight of the surfactant system of a linear alkyl benzene sulfonate;
c) up to 5% by weight of the surfactant system of a nonionic surfactant selected from the group consisting of an alkoxylated fatty alcohol, an amine oxide, or mixtures thereof;
B) from about 0,1% to about 5%, by weight of the composition, of encapsulates, wherein the encapsulates comprise a core and a wall at least partially surrounding the core, wherein the core comprises a benefit agent, and the wall comprises a coating on an outer surface of the wall; and
C) an external structurant.
US Pat. No. 10,455,849

METHOD FOR THE PREPARATION OF A PROTEIN PEPTIDE, A PROTEIN PEPTIDE AND USE THEREOF

INFINITUS (CHINA) COMPANY...

1. A method for the preparation of a protein peptide comprising the steps:(1) mincing tuna from which head and viscera has previously been removed, heating after adding water or heating with water steam to obtain pretreated tuna;
(2) enzymolysing the pretreated tuna, deactivating the enzyme, centrifuging to obtain a supernatant;
(3) concentrating the supernatant and drying to obtain the peptide powder of interest, which is the protein peptide,
wherein the protease used in enzymolysis is one or more of acid protease and NEUTRASE® (neutral, zinc metallo endo-protease from Bacillus amyloliquefaciens), and the total amount of proteases used is 0.2% to 3.2% by weight of the pretreated tuna.
US Pat. No. 10,456,362

STABILIZED PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARING SAME

SAMYANG BIOPHARMACEUTICAL...

1. A method of preparing a pharmaceutical composition, comprising:(a) preparing a solution comprising pemetrexed or a pharmaceutically acceptable salt thereof, and an aqueous solvent in a container;
(b) freezing the solution in the container to produce a frozen product; and
(c) degassing the frozen product under reduced pressure to obtain a degassed and frozen product,
wherein the degassed and frozen product comprises 95 to 100 parts by weight of the solvent per 100 parts by weight of the solvent contained in the solution of step (a), and
the steps of (b) and (c) are performed in a sealed chamber.
US Pat. No. 10,456,874

MANGANESE-CONTAINING, COBALT-BASED HIGH-TEMPERATURE SOLDER ALLOY, POWDER, COMPONENT AND SOLDERING METHOD

SIEMENS AKTIENGESELLSCHAF...

1. A cobalt-based solder alloy comprising:8% by weight—16% by weight of zirconium (Zr);
6% by weight—10% by weight of tantalum (Ta);
0.5% by weight—1.5% by weight of carbon (C),
8% by weight—12% by weight of manganese (Mn);
at least 0.5% by weight of titanium (Ti); and
having no boron (B), no silicon (Si), no germanium (Ge) and no gallium (Ga).
US Pat. No. 10,457,901

CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF

Morehouse School of Medic...

1. A method of formulating a cleaning composition, comprising the steps of:(a) grinding an absorbent material to produce a granular absorbent material, wherein the granular absorbent material is selected from the group consisting of ceramic minerals, zeolite, activated carbon, fumed silica, processed clays, cellulosic absorbents, fibrous absorbents and combinations thereof;
(b) coating the granular absorbent material with a biocide to produce a coated absorbent material, wherein the biocide is applied to granular absorbent material by vapor deposition, by a pressure micro droplet spray, or by a fuming or fogging nozzle to form a surface bonded film on the granular absorbent material, and wherein the biocide is selected from the group consisting of silanes, siloxanes, aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides, solutions of silver, solutions of copper and combinations thereof;
(c) mixing the coated absorbent material with a sanitation agent so that the coated absorbent material absorbs the sanitation agent to form the cleaning composition, wherein the sanitation agent is selected from the group consisting of chlorine bleach solutions, hydrogen peroxide solution, peracetic acid, quaternary amine solutions, alcohol solutions and combinations thereof; and
(d) adding to the cleaning composition a modifying agent selected from the group consisting of a tackifier, a thickening agent, a gum, an absorbent polymer, a carboxymethyl cellulose (CMC)-derived polymer, a hierarchically porous carbons (HPC)-derived polymer, or combinations thereof,
wherein the cleaning composition comprises 25-30% (w/w) of the granular absorbent material, 0.5 to 3.5 wt % of the biocide, 0.1 to 10 wt % of the sanitation agent, and 0.1 to 5 wt % of the modifying agent.
US Pat. No. 10,456,363

MODIFIED CYCLODEXTRIN COATED MAGNETITE NANOPARTICLES FOR TARGETED DELIVERY OF HYDROPHOBIC DRUGS

1. Beta-cyclodextrin-citrate coated magnetic nanoparticles having a size of 3 to 10 nm, wherein the beta-cyclodextrin-citrate coated magnetic nanoparticles are free of Beta-cyclodextrin-citrate gum Arabic modified nanoparticles, andwherein the beta-cyclodextrin-citrate coated magnetic nanoparticles are loaded with a hydrophobic drug.
US Pat. No. 10,457,902

SOLID TABLET UNIT DOSE OVEN CLEANER

Ecolab USA Inc., Saint P...

1. A pressed solid detergent composition comprising:an alkali metal hydroxide alkalinity source;
sodium carbonate in an amount between 40 wt. % and 90 wt. %;
an anhydrous silicate secondary alkalinity source in an amount between 1% and 10% by weight of the composition;
water, wherein the total water of the composition is in an amount between 0.1 wt. % and 4 wt. %;
at least two polycarboxylic acid polymers having different molecular weights wherein the at least two polycarboxylic acid polymers comprise an acrylic acid polymer having a molecular weight from 1,000 g/mol to 100,000 g/mol;
an aminocarboxylic acid; and
a phosphonate in an amount less than 1 wt. %,
wherein the polycarboxylic acid polymers, aminocarboxylic acid and phosphonate comprise up to 35 wt. % of the composition.
US Pat. No. 10,455,851

METHODS OF FEEDING PELLETED FEED PRODUCTS TO A RUMINANT

Purina Animal Nutrition L...

1. A method of feeding a pelleted feed product to a ruminant, the method comprising:providing the ruminant a pelleted feed product, the pelleted feed product comprising a micro particle and at least one additional feed component, the micro particle comprising a mixture of at least one active substance and at least one carboxylic acid and/or salt thereof, wherein the mixture is embedded within a fatty substance, further wherein:
the at least one carboxylic acid and/or salt thereof is characterized by the presence of an acidic functional group and at least one lipophilic functional group, and
the at least one active substance includes a basic functional group that interacts with the acidic functional group of the carboxylic acid and/or salt thereof, and the lipophilic functional group adheres to the fatty substance such that the fatty substance defines an outer fat layer that protects the at least one active substance from the at least one additional feed component in the pelleted feed product, and
wherein, in response to ingesting the pelleted feed product, the protected at least one active substance remains protected from ruminal degradation and available for absorption in an intestine.
US Pat. No. 10,456,364

USE OF PROCALCITONIN (PCT) IN RISK STRATIFICATION AND PROGNOSIS OF PATIENTS WITH A PRIMARY, NON-INFECTIOUS DISEASE

B.R.A.H.M.S. GmbH, Henni...

1. A method comprising administering an antibiotic to a patient:wherein the patient has a primary disease not being an infection;
wherein, before administering of the antibiotic, the patient has had a level of analyte of procalcitonin or fragments thereof of at least 50 amino acids in length determined and the level of analyte of procalcitonin or fragments thereof of at least 50 amino acids in length determined is between 0.02 and 0.1 ng/mL.
US Pat. No. 10,456,365

METHODS AND FORMULATIONS FOR SUPPORTING AND PROMOTING BONE HEALTH

1. A method for treating osteoporosis in a human being in need thereof comprising administering to said human being a therapeutically effective amount of ?-Caryophyllene.
US Pat. No. 10,455,853

NUTRITIONAL SUPPLEMENT COMPOSITION SUITABLE FOR IMPROVING LEAN TISSUE MASS STATUS IN AN ADULT HUMAN

UNIVERSITY OF LIMERICK, ...

1. A nutritional supplement suitable for increasing lean tissue mass in a mammal, the supplement comprising per 100 g dry weight at least 60 g of a protein component, 0.01 mg to 0.1 mg vitamin D, and 1 g to 5 g calcium, and in which the protein component comprises:50 g-60 g of a casein-based milk protein composition,
5 g-15 g of a first hydrolysed whey-based milk protein composition having insulinotropic bioactivity; and
4 g-8 g of a second hydrolysed whey-based milk protein composition having antioxidant bioactivity.
US Pat. No. 10,456,366

COMPOSITION AND METHODS FOR TISSUE REGENERATION

Chiou Consulting, Inc., ...

1. A method for reducing gum recession or promoting gum growth in a human in need thereof comprising:administering to the gum of the human in need thereof an effective amount of a topical composition comprising:
a) a gum-growth-promoting agent consisting of from about 10% to about 95% by weight of propylene glycol;
b) a pharmaceutically acceptable medium; and
c) optionally, a cell-growth promoter;
wherein said administering comprises applying the topical composition to the gum area as a uniform layer or injecting topically into various gum areas providing for absorption of a gum receding or gum growth promoting amount of propylene glycol by the gum.
US Pat. No. 10,455,854

NUTRITIONAL COMPOSITIONS CONTAINING STRUCTURED FAT GLOBULES AND USES THEREOF

MEAD JOHNSON NUTRITION CO...

1. A powdered nutritional composition comprising:a carbohydrate source;
a lipid or fat source, wherein the lipid or fat source comprises milk fat globules formed from an enriched lipid fraction derived from bovine milk that has been subjected to a fractionation procedure, further wherein the milk fat globules comprise from about 40 wt. % to about 55 wt. % saturated fatty acids, from about 35 wt. % to about 45 wt. % monounsaturated fatty acids, and from about 1.4 wt. % to about 6 wt. % polyunsaturated fatty acids, based on the total weight of the lipids present in the milk fat globules;
a protein source; and
a preservative.
US Pat. No. 10,456,367

COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY AND OTHER DISORDERS

The Charlotte Mecklenburg...

1. A method of treating a disorder associated with a mutation or loss of function in a fukutin related protein (FKRP) gene in a subject, comprising administering a therapeutically effective amount of a CDP-ribitol to a subject in need thereof daily for at least 30 days, thereby treating the disorder associated with a mutation or loss of function in a fukutin related protein (FKRP) gene in the subject, wherein the disorder associated with a mutation or loss of function in the FKRP gene is selected from the group consisting of limb-girdle muscular dystrophy (LGMD2I), Walker-Warburg syndrome (WWS), muscle-eye-brain disease (MEB), congenital muscular dystrophy (CMD), and any combination thereof.
US Pat. No. 10,456,368

COMPOSITIONS FOR MITIGATING BRAIN TRAUMA AND METHODS THEREOF

1. A formulation for mitigating brain trauma, comprising:one or more ?-3 fatty acids;
one or more curcuminoids;
trans-resveratrol;
?-glycerylphosphorylcholine (“?-GPC”); and
uridine-5?-monophosphate (“UMP”),
wherein the formulation is an oil-based emulsion including the one or more ?-3 fatty acids, the one or more curcuminoids, the trans-resveratrol, the ?-GPC, and the UMP for oral administration.
US Pat. No. 10,455,857

METHOD FOR APPLYING A DESIGN TO A FOOD SUBSTRATE

Ripples Ltd., Petach Tik...

1. A method for applying a design to a food substrate comprising:a. providing an aqueous liquid-phase ink-composition comprising a coffee extract having a viscosity between 2.9 cPs and 5.5 cPs, the liquid-phase ink comprising submicron coffee particles and lacking coffee particles having a diameter exceeding 0.45 microns, wherein the coffee extract is the primary color imparting agent of the aqueous liquid-phase ink-composition wherein the aqueous liquid-phase ink-composition has between 3% and 30% by weight solid component of the coffee extract; and
b. employing a bubble-jet printer to ink-jet the aqueous liquid-phase ink-composition onto the food substrate according to a pattern of the desired design.
US Pat. No. 10,457,909

HIGH YIELD ALGAL BIOMASS PRODUCTION WITHOUT CONCENTRATED CO2 SUPPLY UNDER OPEN POND CONDITIONS

The University of Toledo,...

1. A method for culturing algae, the method comprising:culturing alkaliphilic algae in an open pond medium having a pH above 9.5, sufficient to allow increased fixation of atmospheric CO2 into the open pond medium; and
incorporating into the open pond medium an inorganic carbon buffer, wherein the inorganic carbon buffer comprises HCO3? present at a concentration ranging from 4.5 mM to 60 mM and the open pond medium has a salinity in the range of from about 10 g/L to about 30 g/L and an alkalinity of up to about 1 M;
wherein the open pond medium is free of any concentrated supply of CO2, and no concentrated source of CO2 is used to supply carbon for culturing the alkaliphilic algae.
US Pat. No. 10,457,910

METHOD FOR DEEP DEHYDRATION AND DESICCATION OF CYANOBACTERIA

JIANGSU PROVINCIAL ACADEM...

1. A method for deep dehydration and desiccation of cyanobacteria, comprising:(1) adding a flocculant into a cyanobacteria slurry discharged from an algae-water separation station for conditioning;
(2) pumping the cyanobacteria slurry after the flocculation conditioning into a high pressure diaphragm plate-frame for pressure filtration;
(3) desiccating the cyanobacteria slurry in a quartz glass box after the pressure filtration;
wherein a top surface of said quartz glass box is a quartz glass with high transparency, and material of a periphery and an underside of the box is corrosion-resistant stainless steel,
wherein a polymer hydrophobic membrane is positioned at an inner surface of the quartz glass with high transparency, and contact angles on two surfaces of the polymer hydrophobic membrane are both greater than 75°, and
wherein light transmittance of the quartz glass with high transparency is greater than 90%, average light reflectivity is below 4%, and minimum of the light reflectivity is less than 0.5%.
US Pat. No. 10,456,372

COMBINATION OF UNSAPONIFIABLE LIPIDS COMBINED WITH POLYPHENOLS AND/OR CATECHINS FOR THE PROTECTION, TREATMENT AND REPAIR OF CARTILAGE IN JOINTS OF HUMANS AND ANIMALS

NUTRAMAX LABORATORIES, IN...

1. A formulation for oral administration for the treatment and repair of connective tissue and reduction of inflammation in joints of a human or animal in need thereof comprising avocado/soybean unsaponifiables (ASU) and epigallocatechin gallate (EGCG) provided in synergistically effective amounts.
US Pat. No. 10,457,911

MEDIUM FOR STEM CELL USE

AJINOMOTO CO., INC., Tok...

1. A medium for culturing an iPS cell, comprising:polyvinyl alcohol; and
an albumin,
wherein the albumin and the polyvinyl alcohol are included in the medium in a weight ratio of 1:1.1 to 100, and
an amount of fatty acid binding to the albumin is not more than 2.2 mg per 1 g of the albumin.
US Pat. No. 10,456,373

AGENT EXHIBITING ANTI-STRESS, ANXIOLYTIC AND ANTI-DEPRESSION ACTIVITY, AND COMPOSITION BASED THEREON

1. A composition useful for treating stress, anxiety or depression in a subject, wherein the following components are present within the composition in the following mass percent ratios: 10-90% lithium ascorbate, 6-50% vitamin B6, and 4-40% vitamin B1.
US Pat. No. 10,456,374

PYRROLIDONE CARBOXYLIC ACID (PCA) FOR OPHTHALMIC USE

Laboratori Baldacci S.p.A...

1. A method for treating ocular diseases and/or disorders in a subject, comprising administering to a subject (i) pyrrolidone carboxylic acid and/or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable salt is selected from the group consisting of: carbonate, hydrochloride, hydrobromide, sulfate, hydrogen sulfate, citrate, maleate, fumarate, trifluoroacetate, 2-naphthalenesulfonate, and para-toluenesulfonate, and (ii) one or more active ingredient selected from the group consisting of a metal salt, hyaluronic acid, a cellulose derivative, an osmoprotectant, and a mixture thereof, wherein (i) and (ii) are the only active ingredients administered to the subject.
US Pat. No. 10,456,630

USE OF FARNESENE, POLYFARNESENE AND FARNESENE COPOLYMER FOR GOLF BALLS

Callaway Golf Company, C...

9. A golf ball comprising:a core;
a mantle layer;
a cover;wherein at least one of the core, the mantle layer and the cover comprises a blend material of a highly neutralized ionomer and at least one of a farnesene, a poly(farnesene), or a farnesene copolymer.
US Pat. No. 10,457,657

PROCESSES FOR PREPARING 2,5-FURANDICARBOXYLIC ACID AND ESTERS THEREOF

DUPONT INDUSTRIAL BIOSCIE...

1. A process, comprising:i) oxidizing a feedstock comprising hydroxymethyl furfural and humins in a solvent to produce a mixture comprising crude humins-containing 2,5-furan dicarboxylic acid; and
ii) filtering the mixture under a high temperature of from 50° C. to 275° C. to obtain a filtrate comprising 2,5-furan dicarboxylic acid having a content of 100 ppm or less of humins, wherein the 2,5-furan dicarboxylic acid is soluble in the solvent during the filtering.
US Pat. No. 10,457,913

CORNEAL EPITHELIOID CELLS DERIVED FROM SURFACE ECTODERMAL CELLS

Osaka University, Osaka ...

1. An in vitro or ex vivo method for producing a keratin-12 positive human corneal epithelioid cell, comprising:introducing a lentiviral vector comprising nucleic acids encoding PAX6, KLF4, and OCT4 into a human epithelial cell,
wherein expression of the lentiviral vector induces the production of a keratin 12-positive human corneal epithelioid cell.
US Pat. No. 10,456,631

GOLF BALL INCORPORATING AT LEAST ONE CAST LAYER OF THERMOSET POLYMER MIXTURE HAVING A CENTERING TIME THAT IS INDEPENDENT OF CURE TIME AND IS LOWER THAN THE CENTERING TIME OF THE THERMOSET POLYMER COMPOSITION PORTION OF THE MIXTURE

Acushnet Company, Fairha...

1. A golf ball comprising a subassembly and at least one cast layer formed from a thermoset polymer mixture having a centering time Ct1 and comprising: (i) at least one of a polyurethane composition, a polyurea composition, or a polyurethane/polyurea hybrid composition; and (ii) a treated fumed silica compound in an amount such that centering time Ct1 is independent of the thermoset polymer mixture's degree of cure and lower than a centering time Ct2 of the at least one of a polyurethane composition, a polyurea composition, or a polyurethane/polyurea hybrid composition.
US Pat. No. 10,457,914

OPTIMIZED METHODS FOR DIFFERENTIATION OF CELLS INTO CELLS WITH HEPATOCYTE AND HEPATOCYTE PROGENITOR PHENOTYPES, CELLS PRODUCED BY THE METHODS, AND METHODS FOR USING THE CELLS

Katholieke Universiteit L...

1. A cell culture composition, comprising isolated expanded human non-embryonic, non-germ multipotent adult progenitor cells in a culture medium comprising about 5 ng/ml to about 500 ng/ml Wnt3a and about 10 ng/ml to about 1,000 ng/ml Activin A, characterized in that the multipotent adult progenitor cells can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages, wherein the multipotent adult progenitor cells in the composition are expanded in cell culture for 10-40 doublings prior to being combined with Wnt3a and Activin A, and wherein the amounts of Wnt3a and Activin A are effective to induce the multipotent adult progenitor cells to differentiate into progeny cells with a definitive endoderm phenotype.
US Pat. No. 10,457,915

CHEMICAL DIFFERENTIATION OF PLURIPOTENTSTEM CELLS INTO RETINAL EPITHELIAL CELLS

International Stem Cell C...

1. A method of producing retinal pigmented epithelial cells (RPEs) comprising: a) culturing human pluripotent stem cells (hpSCs) on a feeder layer; b) transferring the hpSCs to feeder layer free culture conditions; c) culturing the hpSCs simultaneously with a ROCK inhibitor, a TGF?R-1 inhibitor, a Wnt inhibitor, and a BMP inhibitor for a period of time sufficient to allow for the production of retinal epithelial progenitor cells; and d) culturing the retinal epithelial progenitor cells with a glycogen synthase kinase 3 (GSK-3) inhibitor, for a period of time sufficient to allow for the production of RPEs, wherein the RPEs express at least one RPE specific markers selected from the group consisting of POU5F1, BEST-1, MITF, OTX2, RLPB1, RPE65, SERPINF1, ZO1, MELANOSOME or a combination thereof.
US Pat. No. 10,456,377

ANESTHETIC COMPRISING TETRACAINE AND A VASOCONSTRICTOR FOR ADMINISTRATION TO A SUBJECT

St. Renatus, LLC, Fort C...

1. A pharmaceutical composition comprising:about 3% (w/v) tetracaine HCl;
about 0.05% oxymetazoline HCl; and
a pharmaceutically acceptable carrier, wherein said pharmaceutical composition has a pH of about 4.0-7.5.
US Pat. No. 10,457,916

METHOD FOR INDUCING DIFFERENTIATION OF INSULIN-PRODUCING CELLS

Tokyo Institute of Techno...

1. A method for directed differentiation into insulin-producing cells, comprising culturing endodermal cells in the following steps (a) to (d):(a) culturing the endodermal cells in a medium comprising a hedgehog signaling inhibitor and an FGF;
(b) culturing the cells obtained in step (a) in a medium comprising a retinoic acid receptor agonist, a hedgehog signaling inhibitor and noggin;
(c) culturing the cells obtained in step (b) in a medium comprising a TGF-? type I activin receptor-like kinase-4/-5/-7 inhibitor and noggin; and
(d) culturing the cells obtained in step (c) in a medium comprising GLP-1 receptor agonist and nicotinamide to produce insulin-producing cells,
wherein the concentration of the noggin in steps (b) and (c) is at least 200 ng/ml or more.
US Pat. No. 10,456,378

FAST ACTING ORALLY DISINTEGRATING FILM

TAHO Pharmaceuticals Ltd....

1. A fast acting orally disintegrating film, comprising:ondansetron or a pharmaceutical acceptable salt thereof in an amount of about 2 to about 24 mg;
a first hydrophilic film forming polymer comprising hydroxylpropylmethylcellulose (HPMC) in a total amount of from about 15% to about 50% by weight of said film, wherein said first hydrophilic film forming polymer is characterized by having a molecular weight of about 5000Da to about 50000Da and viscosity of about 3 cps or about 6 cps;
a second hydrophilic film forming polymer comprising HPMC characterized by having a molecular weight between about 50000Da to about 60000Da and viscosity of about 15 cps, and said first hydrophilic film forming polymer is mixed with said second hydrophilic film forming polymer in a ratio from about 0.3:1 to about 7:1; and
a water soluble excipient comprising polyethylene glycol (PEG) in an amount of about 10% to about 30% by weight of said film;
wherein the fast acting orally disintegrating film disintegrates within about 30 seconds in about 20 cc of water at about 37 degrees Celsius and lightly shaken.
US Pat. No. 10,457,661

METHOD OF RECOVERING LACTIDE

TOYO SEIKAN CO., LTD., T...

1. A method of recovering lactide comprising throwing a polylactic acid and a depolymerization catalyst into an extruder, melt-kneading the polylactic acid and the depolymerization catalyst together in said extruder, feeding said melt-kneaded product thereof from said extruder into a vent chamber maintained under a reduced pressure, depolymerizing the polylactic acid in said vent chamber, gasifying the formed lactide therein, and recovering the gasified lactide from said vent chamber, whereinthe melt-kneaded product of the polylactic acid and the depolymerization catalyst melt-kneaded in the extruder are fed into said vent chamber through a discharge port of said extruder;
the temperature in said extruder is set so that the temperature of said melt-kneaded product is not higher than 270° C. at said discharge port; and
an interior of said vent chamber is set so that the pressure is not higher than 8 kPaA and the temperature is 250 to 330° C. wherein an extrusion screw of the extruder does not extend into the vent chamber.
US Pat. No. 10,457,917

METHODS FOR REPROGRAMMING SOMATIC CELLS

Whitehead Institute for B...

1. A method of making a somatic cell more susceptible to reprogramming to a less differentiated state, comprising: introducing an exogenous nucleic acid encoding an Oct 4 protein operably linked to at least one regulatory sequence into the somatic cell, thereby increasing expression of Oct4 protein in the somatic cell, wherein increased expression of Oct4 protein makes the cell more susceptible to reprogramming; and wherein the exogenous nucleic acid is transiently transfected into the somatic cell.
US Pat. No. 10,457,918

TYROSINE HYDROXYLASE VARIANTS AND METHODS OF USE THEREOF

THE REGENTS OF THE UNIVER...

1. A method of producing L-3,4-dihydroxyphenylalanine (L-DOPA), the method comprising:culturing a host cell to thereby produce L-DOPA,
wherein the host cell is genetically modified to express a heterologous tyrosine hydroxylase, wherein the heterologous tyrosine hydroxylase comprises an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1,
wherein the tryptophan corresponding to amino acid 13 of SEQ ID NO: 1 is replaced with a different amino acid in the heterologous tyrosine hydroxylase, and/or
the phenylalanine corresponding to amino acid 309 of SEQ ID NO: 1 is replaced with a different amino acid in the heterologous tyrosine hydroxylase, and
wherein the heterologous tyrosine hydroxylase is produced in the host cell, and catalyzes the conversion of tyrosine to L-DOPA.
US Pat. No. 10,456,124

APPARATUS AND METHODS FOR SEALING A VASCULAR PUNCTURE

ACCESS CLOSURE, INC., Sa...

1. A sealant for sealing a puncture through tissue, comprising:a mass of PEG precursors comprising PEG-ester precursors and PEG-amine precursors, the PEG-amine precursors including a free-amine form of PEG-amine precursors and a salt form of PEG-amine precursors;
wherein the sealant is provided such that the free-amine form of PEG-amine precursors are at least partially cross-linked with the PEG-ester precursors, and the salt form of PEG-amine precursors remain in an unreactive state until exposed to an aqueous physiological environment, whereupon the salt form of PEG-amine precursors undergo in-situ cross-linking with the PEG-ester precursors to provide adhesion to tissue adjacent the puncture.
US Pat. No. 10,456,380

COMPOSITIONS AND METHODS OF TREATING MUSCULAR DYSTROPHY WITH THROMBOXANE-A2 RECEPTOR ANTAGONISTS

CUMBERLAND PHARMACEUTICLS...

1. A method of treating Duchenne muscular dystrophy in a patient in need of treatment thereof, comprising administering a therapeutically effective amount of a thromboxane A2 receptor antagonist to the patient, wherein the thromboxane A2 receptor antagonist is [1S-(1?,2?,3?,4?)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,457,919

FEEDBACK-RESISTANT ACETOHYDROXY ACID SYNTHASE VARIANT AND METHOD FOR PRODUCING L-VALINE USING THE SAME

CJ CHEILJEDANG CORPORATIO...

1. A polynucleotide encoding an acetohydroxy acid synthase variant in which the 137th amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 3, leucine (L), is substituted with an amino acid other than leucine, and thereby releasing the feedback inhibition to L-valine.
US Pat. No. 10,456,381

COMPOSITIONS AND METHODS FOR TREATING PLASMA CELL DISORDERS AND B-CELL PROLYMPHOCYTIC DISORDERS

Knopp Biosciences LLC, P...

1. A method of treating a condition characterized by elevated levels of B-cells in a subject, comprising:administering to the subject in need thereof, a therapeutically effective amount of dexpramipexole, or pharmaceutically acceptable salt thereof,
wherein the condition is selected from the group consisting of diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma (MZL), small cell lymphocytic lymphoma, mantle cell lymphoma (MCL), Burkitt lymphoma, Waldenstrom's macroblobulinemia, B-cell leukemia, and any combination thereof.
US Pat. No. 10,457,920

STABILIZED HUMICOLA LANUGINOSA LIPASE VARIANTS IN WATER-SOLUBLE FILMS

MONOSOL LLC, Merrillvill...

1. A water-soluble film comprising a variant of a parent lipase, which variant has lipase activity, has at least 60% but less than 100% sequence identity with SEQ ID NO: 2,and comprises substitutions at positions corresponding to T231R+N233R and at least one or more of D96E, D111A, D254S, G163K, P256T, G91T and G38A of SEQ ID NO: 2.
US Pat. No. 10,457,921

LIPASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME

1. A variant of a parent lipase, wherein the variant has at least 90% but less than 100% sequence identity to SEQ ID NO: 2, has lipase activity, comprises a substitution at position 92 and/or 96; and remains unaltered at positions 231, 233 and 254 of SEQ ID NO: 2;wherein the substitution at position 92 is Asp or Lys; and
wherein the substitution at position 96 is IIe, Leu or Thr.
US Pat. No. 10,456,383

TARGETED APPROACH IN THE MANAGEMENT OF EPIDERMOLYSIS BULLOSA

The Board of Trustees of ...

1. A method for the targeted treatment of Epidermolysis Bullosa simplex (EBS) caused by a genetic mutation in one or both of keratin K5 and keratin K14, to improve clinical severity of lesional skin, the method comprisingcontacting topically a lesion of a patient suffering from EBS with an effective dose of a formulation comprising 0.1% to 5% rapamycin.
US Pat. No. 10,457,666

STABLE CRYSTAL FORM OF TIPIRACIL HYDROCHLORIDE AND CRYSTALLIZATION METHOD FOR THE SAME

TAIHO PHARMACEUTICAL CO.,...

1. Crystal Form I of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride exhibiting powder X-ray peaks at two or more angles selected from the group consisting of 11.6°, 17.2°, 17.8°, 23.3°, 27.1°, and 29.3° as a diffraction angle (2?±0.2°), and having a purity of at least 90% by mass.
US Pat. No. 10,457,922

ENGINEERED CASCADE COMPONENTS AND CASCADE COMPLEXES

Caribou Biosciences, Inc....

1. A method of producing a recombinant cell, comprising:facilitating contact of a double-stranded DNA (dsDNA), comprising a first nucleic acid target sequence and a second nucleic acid target sequence, in a host cell with a first engineered Class 1 Type I CRISPR-Cas effector complex and a second engineered Class 1 Type I CRISPR-Cas effector complex,
the first engineered Class 1 Type I CRISPR-Cas effector complex comprising:
a first Cse2 subunit protein, a first Cas5 subunit protein, a first Cas6 subunit protein, and a first Cas7 subunit protein,
a first fusion protein comprising a first Cas8 subunit protein and a first FokI, wherein the N-terminus of the first Cas8 subunit protein or the C-terminus of the first Cas8 subunit protein is covalently connected by a first linker polypeptide to the C-terminus or N-terminus, respectively, of the first FokI, and wherein the first linker polypeptide has a length of between 10 amino acids and 40 amino acids, and
a first guide polynucleotide comprising a first spacer that binds the first nucleic acid target sequence; and
the second engineered Class 1 Type I CRISPR-Cas effector complex comprising:
a second Cse2 subunit protein, a second Cas5 subunit protein, a second Cas6 subunit protein, and a second Cas7 subunit protein,
a second fusion protein comprising a second Cas8 subunit protein and a second FokI, wherein the N-terminus of the second Cas8 subunit protein or the C-terminus of the second Cas8 subunit protein is covalently connected by a second linker polypeptide to the C-terminus or N-terminus, respectively, of the second FokI, and wherein the second linker polypeptide has a length of between 10 amino acids and 40 amino acids, and
a second guide polynucleotide comprising a second spacer that binds the second nucleic acid target sequence,
wherein a protospacer adjacent motif (PAM) of the second nucleic acid target sequence and a PAM of the first nucleic acid target sequence have an interspacer distance of between 20 base pairs and 42 base pairs;
wherein the host cell is outside of a human body; and
wherein contact of the first engineered Class 1 Type I CRISPR-Cas effector complex and the second engineered Class 1 Type I CRISPR-Cas effector complex with the first nucleic acid target sequence and the second nucleic acid target sequence results in cleavage and modification of the dsDNA, thus producing the recombinant cell.
US Pat. No. 10,456,384

METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS)

Salix Pharmaceuticals, In...

1. A method of treating one or more symptoms of irritable bowel syndrome (IBS) in a subject 65 years of age or older, said method comprising administering, for between 14 days and 24 months, 550 mg of rifaximin TID to the subject, thereby treating a symptom of IBS in the subject 65 years of age or older.
US Pat. No. 10,457,923

POLYPEPTIDES HAVING CELLULOLYTIC ENHANCING ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME

Novozymes, Inc., Davis, ...

1. A nucleic acid construct comprising a polynucleotide encoding a GH61 polypeptide having cellulolytic enhancing activity, wherein the polynucleotide is operably linked to one or more heterologous control sequences that direct the production of the GH61polypeptide in a recombinant host cell, and wherein the GH61 polypeptide having cellulolytic enhancing activity is selected from the group consisting of:(a) a GH61 polypeptide having at least 95% sequence identity to the mature polypeptide of SEQ ID NO: 4;
(b) a GH61 polypeptide encoded by a polynucleotide having at least 98% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 3 or the cDNA sequence thereof; and
(c) a GH61 polypeptide comprising SEQ ID NO: 4,or the mature polypeptide of SEQ ID NO: 4.
US Pat. No. 10,457,668

CRYSTALLINE FORMS OF POSACONAZOLE INTERMEDIATE AND PROCESS FOR THE PREPARATION OF AMORPHOUS POSACONAZOLE

BIOCON LIMITED, Kamataka...

1. A process for preparation of crystalline B-3 form of 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)phenyl) piperazin-1-yl)phenyl)-1-((2S,3S)-2-(benzyloxy)pentan-3-yl)-1H-1,2,4-triazol-5(4H)-one (III) comprising of:a) Treating a solution of 1-((2S,3S)-2-(benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one (II) in a polar organic solvent under nitrogen atmosphere with an alkali solution at a lower temperature;
b) Adding ((3S,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl) tetrahydrofuran-3-yl)methyl 4-methylbenzenesulfonate (I) to step a) solution;
c) Adding an aliphatic ester solvent and water to the solution of step b);
d) Separating the layers;
e) Partially concentrating the organic layer and adding an aliphatic hydrocarbon solvent at a lower temperature;
f) Stirring the reaction mass of step e) at elevated temperature; and
g) Cooling the reaction mass of step f), filtering and optionally washing with aliphatic hydrocarbon solvent to provide compound III in crystalline Form B-3.
US Pat. No. 10,457,924

VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS

DANISCO US INC, Palo Alt...

1. A variant ?-amylase polypeptide derived from a parental ?-amylase polypeptide, comprising at least two combinable mutations at productive amino acid positions; wherein the mutations are at position S452 and R142, wherein the variant has at least 99% amino acid sequence identity with SEQ ID NO: 3.
US Pat. No. 10,456,386

PHARMACEUTICAL COMPOSITION COMPRISING BETAHISTINE

OTOLANUM AG, Zug (CH)

1. A pharmaceutical composition for intranasal delivery to a human patient, comprising a solution or suspension of a therapeutically effective amount of betahistine dihydrochloride, a viscosity enhancing agent, a moisturizing agent, and a buffer, wherein the pH of the pharmaceutical composition is about 4.4 to about 6.4.
US Pat. No. 10,457,925

PROCESS FOR THE PRODUCTION OF CELLULOLYTIC AND/OR HEMICELLULOLYTIC ENZYMES

IFP ENERGIES NOUVELLES, ...

1. A process for the production of cellulolytic and/or hemicellulolytic enzymes by a cellulolytic and/or hemicellulolytic microorganism, comprising(a) growing the microorganism in a culture medium in the presence of a source of carbon;
(b) inducing the production of the enzymes by the microorganism in the presence of an inducing substrate, wherein said inducing substrate is a mixture of cellulosic hydrolysates, lactose and a solution of hemicellulosic hydrolysates, the quantities of each of the constituents of the mixture are defined by the following limits:
50% to 65% by weight of cellulosic hydrolysates;
22% to 24% by weight of lactose; and
15% to 25% by weight of a solution of hemicellulosic hydrolysates;
the sum of these three constituents being equal to 100%, and wherein the microorganism belongs to the species Trichoderma reesei which is deleted for catabolic repression by glucose,
wherein the inducing substrate is supplied in a solution having a concentration of 350 to 600 g/L, and
wherein both the source of carbon and the inducing substrate comprise sugar, and wherein the cellulosic hydrolysates and the solution of hemicellulosic hydrolysates are obtained from a pretreatment of lignocellulosic biomass, and/or the cellulosic hydrolysates are obtained directly from a process for the transformation of lignocellulosic biomass into ethanol.
US Pat. No. 10,456,387

PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER

NLS PHARMACEUTICS AG, St...

1. A method for treating an attention deficit hyperactivity disorder (ADHD) in a human patient by at least reducing impulsivity, comprising orally administering to said patient levophacetoperane, or a pharmaceutically acceptable salt thereof, as the sole active ingredient in an amount effective to reduce impulsivity in said patient ranging from about 5 mg to about 20 mg per day.
US Pat. No. 10,457,926

POLYPEPTIDES HAVING XYLANASE ACTIVITY WITH A HIGH CONVERSION RATE OF XYLOSE—CONTAINING POLYSACCHARIDES

Clariant Produkte (Deutsc...

1. A polypeptide having xylanase activity, wherein the polypeptide comprises a variant of SEQ ID No: 2 comprising an amino acid sequence having at least 95%, but less than 100%, sequence identity to SEQ ID No: 2 and wherein the polypeptide converts at least 60 wt.-% of the xylose-containing polysaccharides of neutral steam-exploded wheat straw to xylose and/or xylose-containing oligosaccharides, and glucose under conditions of pH 5 and 50° C. for 24 hours.
US Pat. No. 10,456,388

ANTIHISTAMINE FOR USE IN TREATMENT OF BREAST CANCER

Belina Pharma AB, Helsin...

1. A method of treating breast cancer in a patient diagnosed with breast cancer, the method consisting of administering to the patient an effective amount of desloratadine, wherein the breast cancer is selected from the group consisting of positive and negative ER, PR, her2 breast cancer molecular subtypes, and invasive breast carcinomas, and wherein the patient is not diagnosed with a seasonal allergic condition.
US Pat. No. 10,457,927

MULTIPROTEASE THERAPEUTICS FOR CHRONIC PAIN

Dublin City University, ...

1. A nucleic acid having a nucleotide sequence encoding a polypeptide having a Clostridium botulinum translocation activity, a Clostridium botulinum cell surface binding activity, a first Clostridium botulinum endopeptidase activity and a second Clostridium botulinum endopeptidase activity said nucleic acid sequence being derived from a Clostridium botulinum nucleotide sequence and comprising a single open reading frame encoding, in sequence from carboxy terminus to amino terminus:a) a Clostridium botulinum-derived binding domain comprising an HCN subdomain and an HCC subdomain,
b) a Clostridium botulinum-derived translocation domain,
c) a Clostridium botulinum-derived first endopeptidase domain,
d) and a Clostridium botulinum-derived second endopeptidase domain different from said first endopeptidase domain,wherein, upon expression, each of said first endopeptidase domain and said second endopeptidase domain has a different selective proteolytic activity against a SNARE protein, and wherein said first and second domains endopeptidase are proteolytically active and recognize different amino acid cleavage sites in a SNARE protein.
US Pat. No. 10,456,389

EXTENDED RELEASE NICOTINAMIDE FORMULATION

CONARIS RESEARCH INSTITUT...

1. A pharmaceutical composition comprising extended release granules of nicotinamide that include a granule core and at least 13% w/w of an ethylcellulose film coating, wherein the granule cores have a mean particle size less than 800 ?m and comprise a conductive filler in an amount of 35-79% w/w, wherein the granules are capable of remaining substantially free of static electricity at up to 10% weight gain of ethylcellulose film coating, and wherein the pharmaceutical composition releases the nicotinamide over at least 3 hours when assessed in a USP paddle apparatus operated at 100 rpm using purified water as a release medium.
US Pat. No. 10,457,928

PROTEASE VARIANTS HAVING AN IMPROVED WASHING PERFORMANCE

1. A protease comprising a polypeptide having an amino acid sequence with at least 90% identity to SEQ ID NO: 1 or 2 and having an Asp residue at position 97 and a Glu residue at position 99 wherein numbering is according to SEQ ID NO: 1.
US Pat. No. 10,456,390

COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS

Almirall, S.A., Barcelon...

1. A combination comprising (a) a corticosteroid chosen from budesonide, mometasone furoate, fluticasone propionate and fluticasone furoate and (b) a dual muscarinic antagonist-?2 adrenergic agonist compound, wherein the dual muscarinic antagonist-?2 adrenergic agonist compound is trans-4-[{3-[5-({[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)-1H-1,2,3-benzotriazol-1-yl]propyl}(methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate saccharinate, wherein the combination is in a form for inhalation by a patient, andwherein the combination of the (a) corticosteroid and (b) dual muscarinic antagonist-?2 adrenergic agonist is in a ratio by weight of (b) to (a) in a range chosen from 1:100 to 1000:1.
US Pat. No. 10,457,929

COMPOSITIONS FOR THE TREATMENT OF GLUTEN INTOLERANCE AND USES THEREOF

Glutagen Pty Ltd., Victo...

1. A method for the prophylaxis or treatment of gluten intolerance, the method comprising administering to a subject in need thereof an oral composition that contains a first component comprising caricain at about 5% w/w to about 95% w/w, based on the total weight of the first component of the oral composition, and a second component comprising at least one pharmaceutically acceptable carrier, excipient, or diluent.
US Pat. No. 10,457,930

OIL-BASED MATERIAL-PRODUCING METHOD AND OIL-BASED MATERIAL-PRODUCING APPARATUS

MICROWAVE CHEMICAL CO., L...

1. An oil-based material-producing method, comprising:a placing step of adding water as a dispersion medium and oil-based material-producing microorganisms to a reactor to produce an aqueous slurry consisting of the water, the oil-based material-producing microorganisms and a microwave responsive material;
a microwave irradiation step of irradiating the aqueous slurry in the reactor with microwaves, breaking at least part of the cell walls of the oil-based material-producing microorganisms; and
collecting an oil-based material produced by the oil-based material-producing microorganisms after the microwave irradiation step,
wherein, in the microwave irradiation step, when the oil-based material-producing microorganisms are irradiated with microwaves in a presence of the microwave responsive material, the microwave responsive material is either one of a microwave-absorbing material and a microwave-sensitive material,
wherein the microwave responsive material is able to flow,
wherein the microwave responsive material has a shape for collecting electric field of microwaves,
wherein the microwave responsive material is a conductive substance, and
wherein the shape of the microwave responsive material is a grain shape having a surface provided with multiple pointed projections.
US Pat. No. 10,457,933

MICROBIAL STRAIN IMPROVEMENT BY A HTP GENOMIC ENGINEERING PLATFORM

Zymergen Inc., Emeryvill...

1. A functionally agnostic method for rehabilitating and improving the phenotypic performance of a production microbial strain, which does not require prior knowledge regarding the underlying function of a given genetic variation, the method comprising the steps of:a. providing a parental lineage microbial strain and a production microbial strain derived therefrom, wherein the production microbial strain comprises a plurality of identified genetic variations selected from single nucleotide polymorphisms, DNA insertions, and DNA deletions, not present in the parental lineage microbial strain;
b. perturbing the genome of the parental lineage microbial strain to add one or more of the identified genetic variations present in the production microbial strain, or perturbing the genome of the production microbial strain to remove one or more of the identified genetic variations not present in the parental lineage microbial strain, to create an initial library of microbial strains, wherein each strain in the initial library comprises a genetic variation from the plurality of identified genetic variations between the parental lineage microbial strain and the production microbial strain, and wherein at least one of the strains of the initial library comprises a genetic variation that does not have a known enzymatic or regulatory function;
c. screening and selecting individual strains of the initial library for phenotypic performance improvements over a reference microbial strain, thereby identifying genetic variations that confer phenotypic performance improvements;
d. providing a subsequent plurality of microbes that each comprise a combination of genetic variations from the genetic variations present in at least two individual microbial strains screened in the preceding step, to thereby create a subsequent library of microbial strains;
e. screening and selecting individual strains of the subsequent library for phenotypic performance improvements over the reference microbial strain, thereby identifying combinations of genetic variation that confer additional phenotypic performance improvements; and
f. repeating steps d)-e) one or more times, in a linear or non-linear fashion, until a microbial strain exhibits a desired level of improved phenotypic performance compared to the phenotypic performance of the production microbial strain, wherein each subsequent iteration creates a new library of microbial strains, where each strain in the new library comprises genetic variations that are a combination of genetic variations selected from amongst at least two individual microbial strains of a preceding library; and
wherein the method enables analyzing genome-wide combinatorial effects of genetic variations across multiple disparate genomic regions, including uncharacterized genes and/or genes of no known function.
US Pat. No. 10,456,396

DRY EYE TREATMENTS

Oyster Point Pharma, Inc....

1. A method of treating dry eye in an individual in need thereof, comprising administering between 5 micrograms and 600 micrograms of varenicline in alternating nostrils of the individual.
US Pat. No. 10,457,936

MASSIVELY PARALLEL CONTIGUITY MAPPING

UNIVERSITY OF WASHINGTON ...

1. A method for capturing contiguity information comprising:(a) producing tagged end fragments of a nucleic acid molecule in situ on a flowcell by:
(i) adding a flowcell compatible end adaptor to each end of a target DNA molecule, wherein each of the end adaptors comprises a first flowcell sequence;
(ii) physically constraining each end of the target DNA molecule at locations on a flowcell by permitting the first flowcell sequences of each end adaptor to hybridize to flowcell surface-bound primers; and
(iii) treating the target DNA molecule physically constrained to the flowcell with at least one transposase loaded with flowcell compatible insertion adaptors resulting in fragmentation of the target DNA molecule and insertion of an insertion adaptor to each resulting fragment end to provide tagged end fragments of the target DNA molecule that remain physically constrained to the flowcell at their respective locations in step (ii), wherein the insertion adaptors comprise a second flowcell sequence;
(b) performing cluster amplification of the tagged end fragments on the flowcell to produce clusters;
(c) sequencing the tagged end fragments; and
(d) capturing contiguity information by associating sequences of the tagged end fragments to provide paired-end reads of the nucleic acid molecule.
US Pat. No. 10,457,937

METHODS AND DEVICES FOR MICRO-ISOLATION, EXTRACTION, AND/OR ANALYSIS OF MICROSCALE COMPONENTS IN AN ARRAY

CALIFORNIA INSTITUTE OF T...

1. A method of barcoding a sample having a target gene sequence, comprising:providing at least one gene primer pair formed by a gene forward primer and a gene reverse primer and at least one barcode primer pair formed by a barcode forward primer and a barcode reverse primer,
wherein the barcode forward primer comprises a first barcode a first bridge sequence at a 3? end region of the barcode forward primer and a forward additional sequence at a 5? end region of the barcode forward primer the forward additional sequence specific to a well barcode, the well barcode associated to and identifying a well on a support, the barcode reverse primer comprises a second barcode, a second bridge sequence at a 3? end region of the barcode reverse primer and a reverse additional sequence at a 5? end region of the barcode reverse primer the reverse additional sequence specific to a well barcode, the well barcode associated to and identifying a well on a support, and
wherein the gene forward primer and the gene reverse primer each comprises a sequence at a 3? end region complementary to a portion of the target gene sequence; the gene forward primer further comprising the first bridge sequence at a 5? end region of the gene forward primer and the gene reverse primer further comprising the second bridge sequence at a 5? of the gene reverse primer;
combining the sample with the at least one gene primer pair and the at least one barcode primer pair to form a mixture; and
performing polynucleotide amplification reaction with the mixture to yield at least one amplicon comprising the first barcode, the second barcode and the target sequence.
US Pat. No. 10,455,886

EPOXIDISED NATURAL RUBBER BASED BLEND FOR ANTISTATIC FOOTWEAR APPLICATION

LEMBAGA GETAH MALAYSIA, ...

1. A method for preparation of epoxidized natural rubber based blend for antistatic footwear application and manufacturing comprising: epoxidized natural rubber, carbon blacks, antioxidants, processing oils, processing waxes and vulcanisation agents wherein the method comprises the steps of:(a) adding epoxidized natural rubber to an internal mechanical mixing device;
(b) mixing of epoxidized natural rubber with carbon blacks, processing oils, processing waxes, and antioxidants by using the internal mechanical mixing device to produce masterbatch;
(c) discharge of the masterbatch from the internal mechanical mixing device;
(d) mixing of masterbatch with vulcanisation agents by using an open milling device to produce blend;
(e) discharging the blend from the open milling device; and
(f) vulcanisation of the blend by heating or microwave.
US Pat. No. 10,456,399

METHOD FOR TREATING CANCER PATIENTS WITH SEVERE RENAL IMPAIRMENT

TAIHO PHARMACEUTICAL CO.,...

1. A method for treating cancer which is one of gastrointestinal cancer, large bowel cancer and breast cancer, comprising:detecting a creatinine clearance of a patient; and
orally administering to the patient with a creatinine clearance of less than 30 mL/min a combination drug comprising ?,?,?-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, a daily dose of 30 to 40 mg/m2/day as FTD-equivalent, divided into two to four portions for administration.
US Pat. No. 10,457,938

TTV MIRNA SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER AND AS A TARGET FOR CANCER TREATMENT AND PREVENTION

DEUTSCHES KREBSFORSCHUNGS...

1. A vector comprising a TTV nucleic acid operatively linked to a promoter, wherein the TTV nucleic acid consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-4, 12, and 38-55.
US Pat. No. 10,458,964

METHOD FOR RAPIDLY DETERMINING SULFUR CONTENT IN A PLURALITY OF SAMPLES

1. A method of measuring the sulfur content in a plurality of individual sulfur-containing fiber or article samples, the method comprising the steps of:a) contacting a plurality of sulfur-containing fiber or article samples with an aqueous solution comprising potassium hydroxide to convert the sulfur to potassium sulfate;
b) concurrently and individually combusting the plurality of samples from step a) in a furnace at a temperature of greater than 650° C. to remove essentially all organic materials and produce a plurality of residues;
c) dissolving each of the pluralities of residue in concentrated nitric acid to form individual residue solutions; and
d) analyzing the individual residue solutions with Inductively Coupled Plasma (ICP) Emission Spectrometry to determine the sulfur content of each sample.
US Pat. No. 10,456,400

AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT

MUSC Foundation for Resea...

1. A compound, wherein the compound is:6H-indolo[2,3-b][1,5]naphthyridine;
6-propyl-6H-indolo[2,3-b][1,5]naphthyridine;
10-propyl-10H-indolo[2,3-b][1,7]naphthyridine;
9-methyl-6-propyl-6H-indolo[2,3-b][1,5]naphthyridine;
7-methyl-10-propyl-10H-indolo[2,3-b][1,7]naphthyridine;
9-methoxy-6-propyl-6H-indolo[2,3-b][1,5]naphthyridine;
9,11-dimethyl-6-propyl-6H-indolo[2,3-b][1,5]naphthyridine;
9-chloro-6-propyl-6H-indolo[2,3-b][1,5]naphthyridine;
7-chloro-10-propyl-10H-indolo[2,3-b][1,7]naphthyridine;
9-methoxy-6H-indolo[2,3-b][1,5]naphthyridine;
7-methoxy-10H-indolo[2,3-b][1,7]naphthyridine;
6H-indolo[2,3-b][1,5]naphthyridin-9-ol;
7-methoxy-6H-indolo[2,3-b][1,5]naphthyridine;
7-methoxy-10-propyl-10H-indolo[2,3-b][1,7]naphthyridine;
9-methyl-6H-indolo[2,3-b][1,5]naphthyridine;
11-butyl-9-methoxy-6H-indolo[2,3-b][1,5]naphthyridine;
6-acetyl-6H-indolo[2,3-b][1,5]naphthyridin-9-yl acetate; or
9-(trifluoromethoxy)-6H-indolo[2,3-b][1,5]naphthyridine,or a pharmaceutically acceptable salt or tautomer thereof.
US Pat. No. 10,457,939

NEUROPROTECTIVE MOLECULES AND METHODS OF TREATING NEUROLOGICAL DISORDERS AND INDUCING STRESS GRANULES

1. A neuroprotective molecule consisting of:(i) a sequence of 25-35 contiguous nucleotides that is identical to a contiguous sequence between nucleotide 1 and nucleotide 50 of a mature human transfer ribonucleic acid (tRNA) having a sequence selected from the group consisting of SEQ ID NOs: 10 and 58-62, wherein a first nucleotide of the 25-35 contiguous nucleotides corresponds to nucleotide position 1 of the mature human tRNA sequence; at least part of the sequence of 25-35 contiguous nucleotides forms a D-loop stem structure;
(ii) optionally a 5? monophosphate, one or more modified nucleotides, and/or one or more modifications in a phosphate backbone in the nucleotide(s) in (i) of the neuroprotective molecule; and
(iii) optionally a 5?-protective group and/or a 3?-protective group;
wherein at least four contiguous nucleotides in (i) of the neuroprotective molecule at the 5?-end are guanosine deoxyribonucleotides; and the neuroprotective molecule is capable of decreasing protein translation in a rabbit reticulocyte assay.
US Pat. No. 10,461,269

CROSSLINKABLE, /POLYMERIZABLE AND COMBINATIONS THEREOF CHARGE-TRANSPORTING MOLECULAR GLASS MIXTURES, LUMINESCENT MOLECULAR GLASS MIXTURES, OR COMBINATIONS THEREOF FOR ORGANIC LIGHT EMITTING DIODES AND OTHER ORGANIC ELECTRONICS AND PHOTONICS APPLICATIONS A

Molecular Glasses, Inc., ...

1. A method of manufacturing an organic device comprising:a) providing a substrate;
b) providing a first set of addressing electrodes over the substrate;
c) forming an organic hole-transporting layer over the first set of addressing electrodes and over the substrate;
d) forming an organic light-emitting layer over the organic hole-transporting layer, the light-emitting layer comprising a crosslinkable non-polymeric organic light-emitting layer, wherein the light-emitting layer is plasticized with a compatible low-Tg crosslinkable additive and has a glass transition temperature (Tg) below 80 degrees Celsius;
e) forming a dopant layer over the organic light-emitting layer and patterning such dopant layer to form color pixels, said color pixels comprising color subpixels wherein the colored subpixels are formed by diffusing the patterned dopant layer into the organic light-emitting layer by thermal annealing at a temperature below 80 degrees Celsius without a solvent;
f) after all the color subpixels are formed, subjecting the organic light-emitting layer to actinic energy to crosslink the low-Tg crosslinkable additive organic light-emitting layer, and increase the thermal properties of the organic light-emitting layer;
g) forming an organic electron-transporting layer over the doped organic light-emitting layer; and
h) forming a second set of addressing electrodes over the organic electron-transporting layer so that the color subpixels can be individually addressed.
US Pat. No. 10,456,401

THERAPEUTIC METHODS AND COMPOSITIONS

Innovus Pharmaceuticals, ...

1. A method to improve erection hardness, erection maintenance, frequency of intercourse, partner satisfaction, or overall satisfaction with sexual health in a male human comprising administering (1) PDE5 inhibitor selected from the group consisting of sildenafil, tadalafil, and vardenafil, and (2) piperine, to the male human.
US Pat. No. 10,457,940

AAV TREATMENT OF HUNTINGTON'S DISEASE

University of Massachuset...

1. An isolated nucleic acid comprising a transgene encoding one or more mature, single-stranded miRNAs, wherein the nucleic acid sequence of the transgene encoding each mature, single-stranded miRNA comprises the sequence set forth in SEQ ID NO: 7, and is flanked by a heterologous miRNA backbone sequence.
US Pat. No. 10,457,941

METHODS AND COMPOSITIONS TO TREAT LIVER DISEASES AND CONDITIONS

Asociacion Centro de Inve...

1. A method of increasing glycine N-methyltransferase (GNMT) enzyme activity in a cell, the method comprising contacting a cell with an miRNA-inhibitor compound that inhibits at least one of miRNA-873-5p and miRNA-518d-5p in an amount effective to increase GNMT enzyme activity in the cell, wherein the increase in GNMT enzyme activity reduces DNA hypermethylation in the cell.
US Pat. No. 10,458,197

DISINTEGRATABLE POLYMER COMPOSITES FOR DOWNHOLE TOOLS

BAKER HUGES, A GE COMPANY...

1. A disintegrable polymer composite comprising:a polymer component comprising one or more of the following: a cured cyanate ester; a crosslinked unsaturated polyester; or a crosslinked vinyl ester resin and
dissolvable glass comprising about 55 to about 80 wt. % of SiO2, 0 to about 35 wt. % of Na2O, 0 to about 35 wt. % of K2O, 0 to about 20 wt. % of CaO, 0 to about 10 wt. % of MgO, provided that the sum of the weights of Na2O and K2O is about 20 wt. % to about 40 wt. %, wherein each weight percent is based on the total weight of the dissolvable glass, the dissolvable glass having a solubility in water of greater than 15 grams/millimeter at 25° C.;
wherein the composite further comprises an additive different from the dissolvable glass, the additive comprising one or more of the following: CaO; MgO; Ca(OH)2; Mg(OH)2; Mg; Zn; a formate of sodium or potassium; an octoate of Zn or Mn or Cu or Co; a naphthenate of Zn or Mn or Cu or Co; aramid fibers; nylon fibers; cellulosic biodegradable fibers; a water soluble or biodegradable polymer different from the polymer component.
US Pat. No. 10,456,403

SALTS AND SOLID FORM OF A BTK INHIBITOR

PRINCIPIA BIOPHARMA INC.,...

1. A sulfonic acid or carboxylic acid salt of at least one compound selected from (E) isomer, (Z) isomer, and a mixture of (E) and (Z) isomer of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]-pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.
US Pat. No. 10,457,942

EXOSOMES AND MICRO-RIBONUCLEIC ACIDS FOR TISSUE REGENERATION

Cedars-Sinai Medical Cent...

1. A method for producing a therapeutic composition comprising:harvesting a population of exosomes from cardiospheres or cardiosphere-derived cells (CDCs) wherein said exosomes comprise microRNAs mir-210 and miR-146a.
US Pat. No. 10,456,404

TARGETING CGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS

Indiana University Resear...

1. A method for preventing the progression of and/or treating a cystic kidney disease in a subject in need thereof, comprising administering an effective amount of at least one phosphodiesterase inhibitor, at least one pharmaceutically effective phosphodiesterase inhibitor prodrug, at least one pharmaceutically active phosphodiesterase inhibitor metabolite, or a combination thereof to the subject, wherein the phosphodiesterase inhibitor and the pharmaceutically active phosphodiesterase inhibitor metabolite individually inhibits at least one phosphodiesterase selected from the group consisting of: phosphodiesterase type 5; phosphodiesterase type 6; and phosphodiesterase type 9, and the pharmaceutically effective phosphodiesterase inhibitor prodrug is convertible to an active inhibitor of at least one phosphodiesterase selected from the group consisting of: phosphodiesterase type 5; phosphodiesterase type 6; and phosphodiesterase type 9.
US Pat. No. 10,457,943

ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER STEM CELLS

Andes Biotechnologies Glo...

1. A method for treating or suppressing metastatic cancer in an individual comprising administering to the individual an effective amount of one or more oligonucleotide complementary to a human non-coding chimeric mitochondrial RNA molecule comprising:a. an antisense 16S mitochondrial ribosomal RNA covalently linked at its 5? end to the 3? end of a polynucleotide with an inverted repeat sequence or
b. a sense 16S mitochondrial ribosomal RNA covalently linked at its 5? end to the 3? end of a polynucleotide with an inverted repeat sequence,
wherein the one or more oligonucleotide is able to hybridize with the chimeric mitochondrial RNA molecules to form a stable duplex,
wherein the metastatic cancer is selected from the group consisting of bladder cancer, brain cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, liver and bile duct cancer, lung cancer, melanoma, oral cancer, ovarian cancer, pancreatic cancer, pharynx cancer, prostate cancer, renal cancer, testicular cancer, and thyroid cancer, and
wherein the individual has been previously treated for cancer with a therapy.
US Pat. No. 10,457,944

OLIGOMERS

Royal Holloway, Universit...

1. A method of ameliorating Duchenne muscular dystrophy, the method comprising administering an oligomer to a patient, wherein the oligomer comprises at least 25 nucleotides and has a nucleotide sequence that is:a) identical to at least 25 contiguous nucleotides of CXG XXG CCX CCG GXX CXG AAG GXG XXC XXG (SEQ ID NO: 10); or
b) identical to at least 25 contiguous nucleotides of XXG CCX CCG GXX CXG AAG GXG XXC XXG XAC (SEQ ID NO: 12),wherein X=U or T.
US Pat. No. 10,456,406

USE OF A PPAR-? AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB

VTV THERAPEUTICS LLC, Hi...

1. A method of treating muscle atrophy in a subject comprising administering to the subject in need thereof (E)-[4-[3-(4-fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid, or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,457,946

METHODS FOR OVERCOMING GLUCOCORTICOID RESISTANCE AND FOR DETERMINING GLUCOCORTICOID RESISTANCE POTENTIAL IN CANCER

1. A method of sensitizing a cancer cell to glucocorticoid-induced apoptosis or cell death, wherein said cell is resistant to glucocorticoid-induced apoptosis or cell death and wherein the expression level of CASP1 gene and/or NLRP3 gene in said cell is increased as compared to a corresponding glucocorticoid-sensitive control, comprising contacting the cell with an effective amount of an inhibitor of CASP1.
US Pat. No. 10,457,947

TARGETING OF HUMAN GLUCOCORTICOID RECEPTOR BETA IN CANCER

The University of Toldeo,...

1. A composition comprising a peptide nucleic acid (PNA) consisting of the sequence TGCCATACACAGTAT [SEQ ID NO:1].
US Pat. No. 10,456,409

COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING HETEROTOPIC OSSIFICATION AND PATHOLOGIC CALCIFICATION

Nostopharma, LLC, Bethes...

1. A method for preventing or treating heterotopic ossification, vascular calcification, or other pathologic calcification in a patient, comprising administering to said patient a combination of: a) a Hedgehog (Hh) pathway antagonist; and b) vitamin D, cholecalciferol or a vitamin D analog, wherein the combination of said Hh pathway antagonist and said vitamin D, cholecalciferol or vitamin D analog is effective at preventing or treating said heterotopic ossification, vascular calcification, or other pathologic calcification in said patient.
US Pat. No. 10,457,948

BIOPHARMACEUTICAL PRODUCTION METHOD

University of Kent, Cant...

1. A method for the manufacture of a disulphide-requiring biopharmaceutical protein having an element of at least tertiary structure using wild type E. coli, the method comprising:a) culturing wild type E. coli transformed with a plasmid expressing the biopharmaceutical with an N-terminal TorA signal peptide;
b) inducing the E. coli to express the biopharmaceutical protein; and
c) obtaining the biopharmaceutical protein from a periplasmic fraction,wherein:the biopharmaceutical protein comprises no more than two disulphide bonds and has a molecular weight of less than 30 kDa, and
the element of at least tertiary structure is adopted in the cytoplasm of the wild type E. coli.
US Pat. No. 10,456,410

HYDROGEN SULFIDE (H2S) RELEASING DONOR COMPOUND FOR DERMAL WOUND REGENERATION

University of South Carol...

1. A wound dressing comprising:a biodegradable scaffold material; and
a hydrogen sulfide donor, wherein the hydrogen sulfide donor is present in the wound dressing in an amount ranging from about 0.5 millimolar to about 150 millimolar.
US Pat. No. 10,458,461

BEARING SHAFT AND BEARING

NTN CORPORATION, Osaka (...

1. A bearing shaft provided with an outer peripheral surface that includes a raceway surface on which a rolling element rolls,the bearing shaft being made of steel containing carbon of 0.7% by mass or more,
the raceway surface being formed with a nitrogen-enriched layer, and
the absolute value of compressive residual stress in the surface of the nitrogen-enriched layer being 600 MPa or more and 1700 MPa or less.
US Pat. No. 10,456,411

COMPOSITION COMPRISING KETONE BODY AND NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATOR AND METHYL DONOR

Tecton Group, LLC, Memph...

1. A composition comprising a therapeutically effective amount of:(i) an exogenous ketone body present in the composition in an amount from 1 mg to 50,000 mg, wherein the exogenous ketone body comprises 3-hydroxybutyrate (“BHB”) or an ester of BHB;
(ii) an exogenous nicotinamide adenine dinucleotide (“NAD”) modulator; and
(iii) a methyl donor;
wherein the ratio (w/w) of the exogenous ketone body to the exogenous NAD modulator is from 160:1 to 10:1; and
wherein the composition is in a single unit form.
US Pat. No. 10,457,950

GENE TARGETING IN PLANTS USING A CHIMERIC MULTI DOMAIN RECOMBINATION PROTEIN

Algentech SAS, Envry (FR...

1. An isolated nucleic acid molecule that encodes for a chimeric multi domain recombination protein that is able to initiate strand invasion and annealing between single stranded DNA and target DNA in a plant cell and has the functions of:i) donor DNA-Binding;
ii) chromosomal binding;
iii) chromosomal target binding; and
iv) recombination induction,
wherein the multi domain recombination protein comprises a recombination induction domain selected from:
(a) RecA, Rad51 or Rad52; or
(b) a peptide domain of 15 to 50 amino acids from RecA, Rad51 or Rad52, which has recombination inducing activity.
US Pat. No. 10,456,412

LIPID EXTRACTION PROCESSES

Aker BioMarine Antarctic ...

1. A high-efficiency process for extracting lipids from a krill biomass comprising:mixing said krill biomass with a protic solvent having a concentration of from 90% to 97% at a temperature of from about 5° C. to about 65° C. to provide a solvent and krill biomass mixture, wherein said krill biomass is selected from the group consisting of cooked krill meals and krill hydrolysate meals,
separating a crude lipid solution from the solvent and krill biomass mixture, wherein about 70 to 90% w/w of the total available lipids in the krill biomass are extracted;
desalting said crude lipid solution;
fractionating said desalted crude lipid solution by adjusting the dry matter content of said crude lipid solution to from about 10% to 40% while maintaining the concentration of the protic solvent at from about 65% to 98% and holding said solution at about 0° C. to about 20° C. so that phospholipids in said solution partition into a light phase and neutral lipids in said solution partition into a heavy phase; and
separating said heavy and light phases.
US Pat. No. 10,457,951

WHEAT WITH REDUCED LIPOXYGENASE ACTIVITY

ARCADIA BIOSCIENCES, INC....

1. A wheat plant comprising a human induced alteration in an Lpx1 gene in a D genome, wherein milled grain from said wheat plant has a property selected from the group consisting of: (a) increased shelf-life; (b) increased oxidative stability; (c) decreased production of Lpx1 protein; (d) decreased lipoxygenase activity; (e) decreased hexanal production; (f) decreased pinellic acid production; (g) decreased decomposition products from fatty acids; and (h) improved sensory characteristics as compared to milled grain from a wild type wheat plant.
US Pat. No. 10,457,952

ISOLATED POLYNUCLEOTIDES AND POLYPEPTIDES, AND METHODS OF USING SAME FOR IMPROVING PLANT PROPERTIES

Evogene Ltd., Rohovot (I...

1. A method of increasing abiotic stress tolerance, yield, biomass, growth rate, vigor, and/or nitrogen use efficiency of a plant, comprising over-expressing within the plant a polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 512 as compared to a native plant of the same species which is grown under the same growth conditions, wherein said polypeptide is over-expressed by introducing into the plant a heterologous polynucleotide encoding said polypeptide, wherein said amino acid sequence increases the abiotic stress tolerance, yield, biomass, growth rate, vigor, and/or nitrogen use efficiency of the plant.
US Pat. No. 10,457,697

METHOD OF STABILIZING IMINO-FUNCTIONAL SILANE

Momentive Performance Mat...

1. A method of stabilizing imino-functional silane comprising:a) adding a Brønsted-Lowry base to an imino-functional silane; and,
b) mixing the imino-functional silane with the Brønsted-Lowry base to provide stabilized imino-functional silane.
US Pat. No. 10,457,953

TOBACCO PLANTS EXHIBITING ALTERED PHOTOSYNTHESIS AND METHODS OF MAKING AND USING

Altria Client Services LL...

1. A method of making a Nicotiana tabacum plant, comprising:inducing mutagenesis in N. tabacum cells to produce mutagenized N. tabacum cells;
obtaining one or more N. tabacum plants from said mutagenized N. tabacum cells; and
identifying at least one of said N. tabacum plants that comprises a mutation in a sequence having at least 95% sequence identity to SEQ ID NO:15 or 17.
US Pat. No. 10,458,979

SOLID SUPPORTED ARTIFICIAL CELL MEMBRANE SYSTEM

Agency for Science, Techn...

1. An artificial cell membrane system comprising:(i) at least one supported membrane protein carrier comprising a polymeric vesicle comprising a circumferential membrane comprising amphiphilic block copolymers, wherein at least one protein is integrated, embedded or inserted in the circumferential membrane of amphiphilic block copolymers via in vitro synthesis, wherein the supported membrane protein carrier comprises a mean diameter of less than 500 nm; and
(ii) a free floating polystyrene microsphere (PS-SA) bead or scintillation proximity assay (SPA) bead suspended in a fluid medium, wherein the PS-SA bead or SPA bead comprises a mean diameter of less than 5 ?m,
wherein the at least one supported membrane protein carrier comprises a direct attachment to a surface of the PS-SA bead or SPA bead, wherein the direct attachment comprises a physisorption attachment, a chemisorption attachment, or combinations thereof, and wherein the surface of the PS-SA bead or SPA bead is decorated with the polymeric vesicle.
US Pat. No. 10,456,415

OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN

ASTEX PHARMACEUTICALS, IN...

1. A method of treating a condition, the method comprising administering to a subject in need thereof a therapeutically-effective amount of a dinucleotide analogue, or a pharmaceutically-acceptable salt thereof, wherein the dinucleotide analogue, or the pharmaceutically-acceptable salt thereof, is of the formula: 5?-DpG-3? or 5?-GpD-3?, wherein D is decitabine; p is a phospholinker; and G is deoxyguanosine, wherein the number of phosphorus atoms in the phospholinker is one, wherein the linker is not a phosphorothioate linker.
US Pat. No. 10,457,954

ISOLATED POLYNUCLEOTIDES AND POLYPEPTIDES, AND METHODS OF USING SAME FOR INCREASING NITROGEN USE EFFICIENCY, YIELD, GROWTH RATE, VIGOR, BIOMASS, OIL CONTENT, AND/OR ABIOTIC STRESS TOLERANCE

Evogene Ltd., Rehovot (I...

1. A method of increasing harvest index, leaf blade area, plot coverage, and/or rosette area of a plant, comprising:(a) over-expressing within the plant an exogenous polynucleotide comprising a nucleic acid sequence encoding the polypeptide selected from the group consisting of SEQ ID NOs: 656, 3402, 3403, 3404 and 3405, wherein said exogenous polynucleotide is operably linked to a heterologous constitutive promoter, and
(b) selecting the plant resulting from step (a), said plant overexpressing said exogenous polynucleotide, under nitrogen-limiting conditions which comprise between 0.75-3 millimolar (m M) nitrogen, for an increased harvest index, leaf blade area, plot coverage, and/or rosette area as compared to a non-transformed plant which is grown under the same growth conditions,
(c) isolating the plant or a regenerable portion of said plant selected according to step (b) having said increased harvest index, leaf blade area, plot coverage, and/or rosette area under said nitrogen-limiting conditions so as to obtain an isolated plant or a regenerable portion of said selected plant, and
(d) planting said isolated plant obtained in step (c) or regenerating a plant from said regenerable portion obtained in step (c) to thereby obtain a plant characterized by said increased harvest index, leaf blade area, plot coverage, and/or rosette area under said nitrogen-limiting conditions as compared to said non-transformed plant which is grown under the same growth conditions,
thereby increasing the harvest index, leaf blade area, plot coverage, and/or rosette area of the plant.
US Pat. No. 10,456,416

COMPOSITIONS AND METHODS OF TREATING MICROBES

Plurogen Therapeutics, LL...

1. A composition for treating a microbial infection consisting essentially of:a poloxamer at a concentration ranging from about 45 to about 55% w/w, the poloxamer consisting essentially of poloxamer 127, poloxamer 188, poloxamer 237, poloxamer 335, poloxamer 407 and combinations thereof,
glycerin at a concentration ranging from about 1 to about 3% w/w,
a preservative at a concentration ranging from about 0.1 to about 2% w/w,
a pH adjuster, and
water.
US Pat. No. 10,457,955

PLANT PROMOTER FOR TRANSGENE EXPRESSION

Dow AgroSciences LLC, In...

1. A nucleic acid vector comprising a promoter operably linked to:a) a polylinker sequence; or,
b) a heterologous coding sequence;
wherein said promoter comprises a polynucleotide sequence that has at least 98% sequence identity with SEQ ID NO:1.
US Pat. No. 10,458,981

THREE-STEP ACID DISSOCIATION ENZYME LINKED IMMUNOSORBENT (TADELIS) ASSAY

Hoffmann-La Roche Inc., ...

1. A method for determining in a sample the total amount of a ligand of a ligand-binding protein therapeutic comprising the following steps in the following order:subjecting the sample to an acid treatment,
forming in solution a ternary complex comprising
i) an anti-ligand antibody,
ii) the ligand, and
iii) labelled ligand-binding protein,
by adding first the labelled ligand-binding protein to the sample to form a binary labelled ligand-binding protein-ligand complex, and by adding after the formation of the binary complex the anti-ligand antibody to the sample to form a ternary labelled ligand-binding protein-ligand-anti-ligand antibody complex, and
determining the amount of the ternary complex,andthereby determining the amount of the ligand of the ligand-binding protein.
US Pat. No. 10,456,417

SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS

Hope Medical Enterprises,...

1. A pharmaceutical composition comprising sodium nitrite and ethylenediaminetetraacetic acid (EDTA), wherein the sodium nitrite contains no greater than 0.02% by weight of sodium carbonate, contains no greater than 10 ppm of an anti-caking agent, has a loss on drying of no greater than 0.25% by weight, wherein the water content is no greater than 0.5% by weight, wherein the heavy metal content is no greater than 10 ppm, contains no greater than 0.4% by weight of sodium nitrate, contains no greater than 0.005% by weight of insoluble matter, contains no greater than 0.005% by weight of chloride, contains no greater than 0.01% by weight of sulfate, contains no greater than 0.001% by weight of iron, contains no greater than 0.01% by weight of calcium, contains no greater than 0.005% by weight of potassium, contains no greater than 0.05 ppm of mercury, contains no greater than 2 ppm of aluminum, contains no greater than 3 ppm of arsenic, contains no greater than 0.003% by weight of selenium, contains no greater than 5000 ppm of ethanol, contains no greater than 3000 ppm methanol, wherein the total non-volatile organic carbon content is no greater than 10 ppm, and contains no greater than 0.25 EU/mg of bacterial endotoxins.
US Pat. No. 10,457,956

SCN PLANTS AND METHODS FOR MAKING THE SAME

UNIVERSITY OF TENNESSEE R...

1. An elite soybean plant, or a part thereof, comprising an introgression or genetic modification resulting in the elite soybean plant or a part thereof an increased expression of: an miRNA selected from SEQ ID NOs: 12, 25 and 34 and/or the gene of SEQ ID NO: 196, wherein compared to the host soybean plant or a part thereof used to produce the elite soybean plant or a part thereof, the elite soybean plant or a part thereof exhibits an increased resistance to an SCN infection.
US Pat. No. 10,456,418

PREPARATION OF PHARMACEUTICAL DOSAGE FORMS CONTAINING IRON (III) SALTS

Navinta, LLC, Ewing, NJ ...

1. A process for directly preparing a liquid pharmaceutical dosage form of ferric pyrophosphate citrate complex composition comprising:mixing a citrate ion source, a pyrophosphate ion source, a sodium ion source, and a ferric ion source in an aqueous based vehicle carrier to form a mixture having an acidic pH;
heating the mixture above room temperature to form a solution;
cooling the heated solution to room temperature or below without isolation of a solid form of ferric pyrophosphate citrate complex; and
adding water to the cooled solution to adjust the ferric ion concentration to about 10 to 250 mM.
US Pat. No. 10,457,957

INSECTICIDAL PROTEINS AND METHODS OF USE

PIONEER HI-BRED IINTERNAT...

1. A polynucleotide comprising a heteroloqous regulatory element operably linked to an isolated nucleic acid molecule encoding a three-domain insecticidal protein comprising a polypeptide sequence having at least 80% sequence identity to SEQ ID NO: 2 and the following protein structure is present in the three-domain insecticidal protein:a) a Domain I, comprising
i) a surface hydrophobic patch comprising
residues corresponding to Phe26, Val48, Pro50, Ile52, Tyr56, Met193, Val202, His205, Tyr206, Phe207, Trp208, Phe209, and Leu210 of SEQ ID NO: 2;
ii) an anti-parallel ?-sheet with four short strands and four ?-helices designated as helix 1, helix 2, helix 3 and helix 4; and
iii) a type 1? ?-turn comprising an amino acid sequence motif as represented by SEQ ID NO: 25;
b) a Domain II; and
c) a Domain III, wherein the surface of Domain II and Domain III comprises a stripe of solvent exposed serine and threonine residues.
US Pat. No. 10,458,983

METHOD FOR DETECTING BIOLOGICAL MATERIAL

KONICA MINOLTA, INC., To...

1. A detection method for specifically detecting a target substance from a pathological specimen, said method comprising the steps of:immunostaining said specimen with a fluorescent label;
immobilizing the immunostained specimen with an immobilization solution; and
mounting the immobilized specimen using an oil-based mounting medium comprising an organic solvent not freely miscible with water and a phenolic discoloration inhibitor which is soluble in said organic solvent,
wherein a section slide prepared using said oil-based mounting medium comprising said phenolic discoloration inhibitor is transparent,
said phenolic discoloration inhibitor is selected from the group consisting of phenols derived from natural products and hindered phenols,
the phenols derived from the natural products are rutin, catechin, or quercetin, and
the hindered phenols are 2,6-di-tert-butyl-4-hydroxymethylphenol, 1,3,5-trimethyl-2,4,6-tris(3,5-di-t-butyl-4-hydroxybenzyl)benzene, or 3,5-di-t-butyl-4-hydroxybenzyl phosphonate diethyl ester.
US Pat. No. 10,456,419

METHOD FOR TREATING MIGRAINE HEADACHES

1. A method for preventing and treating a headache in a patient, comprising:locating one or more ligaments or muscle insertions that are associated with a cervical spine and a skull of the patient; and
injecting into the determined one or more ligaments or muscle insertions an injectable regenerative solution that includes platelet rich plasma (PRP) or stem cells to repair the one or more ligaments or muscle insertions.
US Pat. No. 10,457,958

LEPIDOPTERAN-ACTIVE CRY1DA1 AMINO ACID SEQUENCE VARIANT PROTEINS

Monsanto Technology LLC, ...

1. An engineered insecticidal protein comprising the amino acid sequence as set forth in SEQ ID NO:42.
US Pat. No. 10,456,420

GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CANCER

NantKwest, Inc., San Die...

1. A method for treating cancer in a subject in need thereof comprising administering to the subject a monoclonal antibody having a cytotoxic effect and genetically modified NK-92 cells, wherein the genetically modified NK-92 cells are genetically modified using a plasmid expression vector to generate stable NK-92 cells that express a CD16 polypeptide having a valine at position 158 of the mature form of the CD16 polypeptide; and express interleukin-2 (IL-2) targeted to the endoplasmic reticulum (ER); and further, wherein the expression vector comprises a transgene encoding the CD16 polypeptide and the IL-2 targeted to the ER comprising, in the 5? to 3? direction: a polynucleotide encoding the CD16 polypeptide, an IRES, and a polynucleotide encoding the IL-2 targeted to the ER.
US Pat. No. 10,457,959

EFFICIENT SELECTIVITY OF RECOMBINANT PROTEINS

REGENERON PHARMACEUTICALS...

1. A vector comprising a nucleic acid, wherein the nucleic acid comprises(i) a mammalian tunicamycin (Tn)-resistance gene encoding a protein having at least 93% identity to the amino acid sequence of SEQ ID NO: 3,
(ii) a first a gene of interest (GOI), and
(iii) at least one regulatory element,
wherein the Tn-resistance gene is operably linked to the first GOI and said at least one regulatory element, and
wherein the first GOI encodes a protein selected from the group consisting of an antibody light chain or antigen-binding fragment thereof, an antibody heavy chain or antigen-binding fragment thereof, and an Fc-fusion protein or a fragment thereof.
US Pat. No. 10,455,908

TIMEPIECE OR PIECE OF JEWELLERY MADE OF GOLD

The Swatch Group Research...

18. A timepiece or piece of jewellery manufactured in a nickel free and cobalt free gold alloy, a weight percent composition of which comprises:between 75% and 77.5% gold,
between 1.35 and 1.45% palladium,
between 20.1 and 23.8% copper, and
the nickel free and cobalt free gold alloy further comprises an element chosen from among iridium, rhenium, and ruthenium, wherein
the nickel free and cobalt free gold alloy includes a resistance to a discoloration that yellows a color of the nickel free and cobalt free gold alloy when the nickel free and cobalt free gold alloy is exposed in at least one of a saline atmosphere, an acid atmosphere, and an atmosphere of sweat, and
the resistance to the discoloration of the nickel free and cobalt free gold alloy is greater than that of a 5N red gold alloy according to ISO standard 8654.
US Pat. No. 10,456,421

COMPOSITIONS AND METHODS RELATED TO ENGINEERED ERYTHOID CELLS COMPRISING 4-1BBL

RUBIUS THERAPEUTICS, INC....

1. A genetically engineered enucleated erythroid cell comprising an exogenous polypeptide comprising a 4-1BB-binding fragment of 4-1BBL at the surface of the genetically engineered enucleated erythroid cell,wherein the enucleated erythroid cell was produced by a process comprising:
introducing an exogenous nucleic acid encoding the exogenous polypeptide into a nucleated erythroid cell, or a precursor thereof; and
culturing the nucleated erythroid cell under conditions suitable for enucleation and for production of the exogenous polypeptide.
US Pat. No. 10,457,448

MULTILAYER ALUMINUM CAPSULE

1. A multilayer aluminum capsule made only of aluminum to cover a neck of a bottle, comprising at least two aluminum layers, wherein each of the layers has a thickness between 4 microns and 50 microns, and wherein the capsule is formed by a body and a disc in the upper part of the body.
US Pat. No. 10,457,704

SEPARATION PROCESSES FOR PEA PROTEIN

1. A process for the separation of pea protein, said process comprising the steps of:i. providing an aqueous extract of pea protein or a solution of pea protein, said extract or solution of pea protein comprising at least two types of pea proteins;
ii. passing said aqueous extract or solution of pea protein through at least one expanded bed absorption process, wherein said expanded bed absorption process comprises contacting said aqueous extract or solution of pea protein with at least one adsorbent resin which selectively adsorbs at least a first type of pea protein to provide a non-bound protein fraction and a bound protein fraction, said adsorbent resin comprising:
at least one ligand (L1), said at least one ligand (L1) comprising an aromatic or heteroaromatic ring system and one or more acidic groups, or
at least one ligand (L2), said at least one ligand (L2) comprising an alkylamine or alkylarylamine, wherein said alkylamine or alkylarylamine moieties in ligands (L2) comprise an amine substituted with one or more groups selected from:
a. an aryl, benzyl or heteroaryl group;
b. an alkyl group having 4-16 carbon atoms which may be straight, branched or cyclic;
or combinations thereof;
iii. isolating said first type of pea protein from said adsorbent resin, by elution of either the non-bound protein fraction or of the bound protein fraction; and
iv. isolating the second type of pea protein from said adsorbent resin to provide a second pea protein composition which is depleted in said first type of pea protein.
US Pat. No. 10,457,960

METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAS

Regeneron Pharmaceuticals...

1. An in vitro method for making a biallelic modification to a genomic target locus in a genome within a cell, comprising:(I) introducing into a population of cells:
(a) a Cas protein;
(b) a first guide RNA that hybridizes to a first CRISPR RNA recognition sequence within the genomic target locus;
(c) a second guide RNA that hybridizes to a second CRISPR RNA recognition sequence within the genomic target locus; and
(d) a targeting vector comprising a nucleic acid insert flanked by a 5? homology arm that hybridizes to a 5? target sequence within the genomic target locus and a 3? homology arm that hybridizes to a 3? target sequence within the genomic target locus;
wherein the genome comprises a pair of first and second homologous chromosomes comprising the genomic target locus; and
wherein the Cas protein cleaves at least one of the first and second CRISPR RNA recognition sequences to generate at least one double-strand break in each of the first and second homologous chromosomes; and
(II) identifying a cell comprising a modified genomic target locus comprising a deletion and/or an insertion, wherein the identifying comprises performing a quantitative modification-of-allele assay and a retention assay,
wherein the modification-of-allele assay comprises:
(a) a gain-of-allele assay to determine a copy number of a region of the nucleic acid insert in a genomic DNA sample from the cell; and/or
(b) a loss-of-allele assay to determine a copy number in the genomic DNA sample of a region of the genomic target locus targeted for deletion, and
wherein the retention assay determines a copy number in the genomic DNA sample of a region of the 5? target sequence to which the 5? homology arm hybridizes and/or determines a copy number in the genomic DNA sample of a region of the 3? target sequence to which the 3? homology arm hybridizes,
wherein the combination of the modification-of-allele assay and the retention assay distinguishes correct targeted insertion of the nucleic acid insert into the genomic target locus from random transgenic insertions of the nucleic acid insert into genomic locations outside of the genomic target locus and/or distinguishes correct targeted deletions from deletions extending beyond the region of the genomic target locus being targeted for deletion.
US Pat. No. 10,458,986

SENESCENT CELL BIOMARKERS

UNIVERSITY OF LEICESTER, ...

1. A method of targeting a senescent cell with a biospecific drug conjugate in a subject, the method comprising administering to the subject a therapeutically effective amount of a senescent cell biospecific drug conjugate,wherein the senescent cell biospecific drug conjugate comprises i) an antibody or an antigen-binding fragment thereof that specifically targets and binds to DEP-1, and ii) a cytotoxic agent, which kills the bound senescent cells,
wherein DEP-1 comprises an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, and
wherein the subject comprises a senescent cell.
US Pat. No. 10,457,705

CARRIER FOR LIGAND IMMOBILIZATION

KANEKA CORPORATION, Osak...

1. A carrier for ligand immobilization, obtained by a process comprising shrinking polysaccharide porous beads such that a shrinkage rate is not less than 10%, and crosslinking the polysaccharide porous beads,wherein
Shrinkage rate (%)=(1?V2/V1)×100
wherein V1 represents a gel volume of the polysaccharide porous beads before the shrinking, and V2 represents a gel volume of the polysaccharide porous beads after the shrinking.
US Pat. No. 10,457,961

CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION

THE BOARD OF TRUSTEES OF ...

1. A system for regulating expression of a target polynucleotide in a lymphocyte, the system comprising:(a) a chimeric receptor polypeptide (receptor) comprising a transmembrane receptor or a fragment thereof, that undergoes a receptor modification including a conformational change or chemical modification upon binding to its ligand, wherein the receptor comprises a cleavage moiety that cleaves a cleavage recognition site; and
(b) a chimeric adaptor polypeptide (adaptor) that binds the receptor in response to the receptor modification, wherein the adaptor comprises a gene modulating polypeptide (GMP) comprising an actuator moiety linked to the cleavage recognition site, and wherein the adaptor does not bind any extracellular ligand,
wherein the target polynucleotide encodes for a protein involved in immune cell regulation, and
wherein the receptor is activatable upon binding of the receptor to the ligand to recruit the adaptor to the receptor, and wherein the receptor releases the actuator moiety from the GMP of the recruited adaptor by action of the cleavage moiety at the cleavage recognition site, to effect regulating expression of the target polynucleotide in the lymphocyte.
US Pat. No. 10,458,987

TUMOR ENERGY METABOLISM PROFILING

1. A diagnostic method for the prediction of tumor prognosis including the likelihood of formation of metastases, relapse occurrence, and/or local recurrence and the provision of a therapy recommendation comprising the steps of(a) incubation of a tumor patient's fresh sample material and a fresh comparative sample material from the patient in a culture medium for a time sufficient to eliminate nutrition, drug and biopsy effects on the energy metabolism in the sample materials:
(b) preparation of a cell homogenate and subcellular fractions from the sample materials of step (a);
(c) determination of enzyme activities of at least one anaerobic key enzyme and at least one aerobic key enzyme of the energy metabolism of the cell homogenate or the subcellular fraction and determination of a quotient for each key enzyme of the enzyme activity determined in the sample material and the enzyme activity determined in the comparative sample material wherein the one or more anaerobic key enzyme is selected from the group consisting of malic enzyme (ME), lactate dehydrogenase (LDH), pyruvate kinase low affinity (PKLA), hexokinase and an acyl-CoA dehydrogenase and wherein the one or more aerobic key enzyme is selected from the group consisting of pyruvate kinase high affinity (PKHA) and cytochrome c oxidase (COX); and
(d) calculation of a ratio of the sum of the anaerobic key enzyme quotients and the sum of the aerobic key enzyme quotients using the quotients determined in step (c) in the sample material and the comparative sample material, wherein a decrease in the ratio of aerobic to anaerobic key enzyme quotients or increase in the ratio of the anaerobic to aerobic key enzyme quotients, when compared to a value for balanced anaerobic and aerobic metabolism, correlates with tumor progression, wherein the patient sample material is selected from the group consisting of tumor tissue slices, tumor cell mass and isolated tumor cells and the comparative sample material is selected from the group consisting of a tumor distant tissue slice and a material which in step (a) is incubated under conditions that up regulate the anaerobic energy metabolism; and
(e) selecting a method of treatment based on the calculated ratio.
US Pat. No. 10,456,423

COMPOSITIONS FOR BIOLOGICAL SYSTEMS AND METHODS FOR PREPARING AND USING THE SAME

SMART Surgical, Inc., Bo...

1. A composition for influencing biological growth comprising:a low pH fluid base, wherein the low pH fluid base comprises dextrose;
mononuclear cells obtained from human umbilical cord blood;
VEGF-A, at a concentration within the composition of between 481 picograms per ml and 895 picograms per ml;
PDGF-BB, at a concentration within the composition of between 807 picograms per ml and 1500 picograms per ml;
EGF, at a concentration within the composition of between 715 picograms per ml and 1329 picograms per ml;
SCF, at a concentration within the composition of between 23 picograms per ml and 45 picograms per ml; and
IL-1RA, at a concentration within the composition of between 2215 picograms per ml and 4114 picograms per ml,
wherein the composition is configured for implantation within a human subject.
US Pat. No. 10,456,424

PANCREATIC ENDOCRINE CELLS AND METHODS THEREOF

Janssen Biotech, Inc., H...

1. A method for generating human pancreatic endocrine cells, comprising differentiating pancreatic endoderm cells into pancreatic endocrine cells by culturing the pancreatic endoderm cells with a medium supplemented with Exendin-4, then removing the medium supplemented with Exendin-4 and subsequently culturing the cells in medium supplemented with hepatocyte growth factor (HGF), Exendin-1 and insulin growth factor (IGF)-1.
US Pat. No. 10,457,963

HETEROLOGOUS PRODUCTION OF 10-METHYLSTEARIC ACID

Novogy, Inc., Camden, MA...

1. A yeast cell comprising a methyltransferase gene encoding a Thermomonospora curvata enzyme tmsB and either a branched (methyl)lipid or an exomethylene-substituted lipid, wherein:the branched (methyl)lipid or exomethylene-substituted lipid is a carboxylic acid, carboxylate, ester, thioester, or amide, and
the branched (methyl)lipid comprises a saturated or unsaturated branched aliphatic chain comprising a branching methyl group or the exomethylene-substituted lipid comprises a branched aliphatic chain that is branched because the aliphatic chain is substituted with an exomethylene group.
US Pat. No. 10,456,425

CONDITIONED MEDIUM OF LIVER PROGENITOR CELLS

FRESENIUS MEDICAL CARE DE...

1. A cell free pharmaceutical composition comprising a pharmaceutically effective amount of a mixture comprising hepatocyte growth factor (HGF), interleukin 6 (IL-6), interleukin 8 (IL-8), macrophage stimulating protein (MSP), and vascular endothelial growth factor (VEGF) in a pharmaceutically acceptable diluent, wherein the VEGF is present at a concentration ranging from 10 to 400 ng/ml.
US Pat. No. 10,457,708

STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDES

1. A recombinant pre-fusion respiratory syncytial virus (RSV) Fusion (F) polypeptide, wherein the polypeptide comprises at least two stabilizing mutations in the F1 and/or F2 domain as compared to the RSV F1 and/or F2 domain in a wild-type RSV F protein, wherein at least one of the stabilizing mutations is a mutation of amino acid residue L at position 203 to I.
US Pat. No. 10,457,964

METHOD FOR INCREASING THE BIOMASS SYNTHESIS CAPACITY OF A PHOTOSYNTHETIC MICROORGANISM

RELIANCE INDUSTRIES LIMIT...

1. A method for increasing the biomass synthesis capacity of a photosynthetic microorganism, wherein the photosynthetic microorganism is selected from the group consisting of algae and cyanobacteria, said method characterized by the following steps:a. cloning at least one gene expressing initiator tRNA-Met1 in a vector;
b. introducing said vector containing said gene into said photosynthetic microorganism; and
c. growing said microorganism on a medium containing a selective agent under conducive conditions and obtaining a photosynthetic microorganism with increased biomass synthesis capacity.
US Pat. No. 10,461,294

SEPARATOR FOR ALKALINE BATTERIES, AND ALKALINE BATTERY USING SAME

KURARAY CO., LTD., Kuras...

1. An alkaline battery separator comprising a nonwoven fabric, whereinthe nonwoven fabric comprises subject fibers;
at least a part of the subject fibers comprise a chelate forming fiber;
the chelate forming fiber has a chelate formable functional group introduced into a fiber material and is capable of forming a chelate with a metal ion;
the subject fibers in the nonwoven fabric further comprise a shape retainable fiber; and
a mass ratio of the chelate forming fiber to the shape retainable fiber, chelate forming fiber/shape retainable fiber, is from 8/92 to 67/33.
US Pat. No. 10,456,426

EGG CHALAZA HYDROLYSATE, METHOD FOR PREPARING THE SAME AND USAGE OF THE SAME

National Taiwan Universit...

1. A method for preparing an egg chalaza hydrolysate comprising the steps of:step 1: defrosting an egg chalaza and washing with distilled deionized water for removal of impurities; taking a first product at a lower layer after centrifugation;
step 2: heating the first product at 95° C. for 10-30 minutes and cooling down; then adding distilled deionized water to get a homogeneous solution of the egg chalaza;
step 3: mixing 100-200 g homogeneous solution of the egg chalaza with a hydrolase at a ratio of 100:1-500:1 (w/w) and getting a first hydrolysate solution after reacting a period of time;
step 4: heating the first hydrolysate solution at 95° C. for 10-30 minutes and cooling down; then taking a second hydrolysate solution at an upper layer after centrifugation; and
step 5: filtering and lyophilizing the second hydrolysate solution to get the egg chalaza hydrolysate.
US Pat. No. 10,457,709

ANTIMICROBIAL PEPTIDES, THEIR VARIANTS AND USES

Chain Antimicrobials Oy, ...

1. An antimicrobial peptide, comprising any of the synthetically prepared peptides selected from the group consisting of SEQ ID NO: 10 having the amino acid peptide sequence defined by RKWRAM1RLHAKRLRK, SEQ ID NO: 11 having the amino acid peptide sequence defined by RKWRAMIRLHAKWLRK, SEQ ID NO: 13 having the amino acid peptide sequence defined by WWRLHAKKKLW, and SEQ ID NO: 15 having the amino acid peptide sequence defined by WWRLHAKWKLW; wherein the peptides have antimicrobial activity against the microbes selected from the group consisting of bacteria, fungi, and yeast.
US Pat. No. 10,457,965

DEHYDROGENASE-CATALYSED PRODUCTION OF FDCA

PURAC BIOCHEM B.V., Gori...

1. A microbial cell comprising an expression construct for expression of a nucleotide sequence encoding a dehydrogenase having an amino acid sequence with at least 81.65% identity with the amino acid sequence of SEQ ID NO: 1, wherein, the expression construct is expressible in the cell and expression of 5-hydroxymethyl-2-furancarboxylic acid (HMFCA) dehydrogenase confers to or increases in the cell the ability to oxidize HMFCA to 5- formyl-2-furoic acid (FFA), as compared to a corresponding wild type cell lacking the expression construct.
US Pat. No. 10,458,991

SELECTIVE NEAR-INFRARED OPTICAL IMAGING OF NECROTIC CELLS AND SIMULTANEOUS CELL FIXING AND COUNTER STAINING WITH METALLACROWN COMPLEXES

The Regents of the Univer...

1. A method for simultaneously fixing and staining cells, the method comprising:initially incubating the cells in a solution including a Ln(III)Zn16(HA ligand)16 metallacrown complex, wherein the HA ligand is a hydroximate ligand;
exposing the incubating cells to ultraviolet (UV) light; and
continuing to incubate the cells in the solution after UV light exposure.
US Pat. No. 10,456,427

METHOD OF TREATING VIRAL DISEASES AND PROLIFERATIVE DISORDERS

Lobster Unlimited LLC, O...

1. A method of treating a proliferative disorder in a mammal afflicted therewith, said method comprising internally administering an effective amount of lobster hemolymph, lobster hemocyanin, or a derivative of lobster hemocyanin.
US Pat. No. 10,457,710

ANTIMICROBIAL PEPTIDES, THEIR VARIANTS AND USES

Chain Antimicrobials Oy, ...

1. An antimicrobial peptide, comprising any of the synthetically prepared peptides selected from the group consisting of SEQ ID NO: 32 having the amino acid peptide sequence defined by KWIVWRWRFKR, SEQ ID NO: 34 having the amino acid peptide sequence defined by RRIVKLRWFKR, SEQ ID NO: 35 having the amino acid peptide sequence defined by RRLIWRRFKWLR, SEQ ID NO: 36 having the amino acid peptide sequence defined by KRIVRWRTRKR, SEQ ID NO: 37 having the amino acid peptide sequence defined by KRIVRWRWRKR, and SEQ ID NO: 39 having the amino acid peptide sequence defined by WRILRWRKLKR, SEQ ID NO: 40 having the amino acid peptide sequence defined by WRIVRWRKLKR, and SEQ ID NO: 41 having the amino acid peptide sequence defined by WRIVQWRKLKR, wherein the peptides have an antimicrobial activity against the microbes selected from the group consisting of bacteria, fungi, and yeast.
US Pat. No. 10,456,428

METHOD OF TREATING PSORIASIS

GENMONT BIOTECH INC., Ta...

1. A method, of treating psoriasis, comprising:administrating to subject in need thereof, an effective amount of a composition comprising Lactobacillus paracasei GMNL-653 and a pharmaceutically acceptable carrier, wherein the Lactobacillus paracasei GMNL-653 is deposited in the China Center for Type Culture Collection (CCTCC) with an accession number of CCTCC M2016226 on 25 Apr. 2016, wherein the Lactobacillus paracasei GMNL-653 has an ability to inhibit the formation of cytokine IL-17 and an ability to inhibit the formation of cytokine IL-6.
US Pat. No. 10,457,455

MEMBER FOR USE IN UNDERSEA APPLICATIONS

Intertape Polymer Corp., ...

1. A member for use in undersea applications comprising a plurality of conduits assembled into a bundle; the conduit being an unbonded, flexible, continuous, spoolable tube; the bundle being wrapped with a pressure-sensitive tape comprising:a backing consisting of a polymeric film; and
a layer of corrosion resistant liquid crystal polymer (LCP) yarn of filaments of polyester of 2-naphthalene-6-carboxylic acid and 4-hydroxy benzoic acid oriented parallel to the length of the tape and adhered directly to the polymeric film by a first pressure sensitive adhesive;
a second pressure sensitive adhesive coated on the first pressure sensitive adhesive and LCP filaments, the second pressure sensitive adhesive defining a functional adhesive layer of the tape, wherein the second pressure sensitive adhesive is the same as the first pressure sensitive adhesive; and
wherein the tape is constructed such that it provides an initial tensile strength of at least 1000 lb/in.
US Pat. No. 10,457,711

DERMATOPHAGOIDES FARINAE PROTEIN

TAIHO PHARMACEUTICAL CO.,...

1. A method for preventing or treating an allergic disease caused by Dermatophagoides farinae, the method comprising administering a Dermatophagoides farinae protein selected from the group consisting of (a), (b) and (c) below, or a fragment peptide comprising 10 to 34 amino acid residues of (a), (b) or (c) below, to a patient in need thereof:(a) a protein comprising the amino acid sequence of SEQ ID NO:2;
(b) a protein comprising an amino acid sequence in which one to ten amino acids have been substituted or deleted, and/or one or several amino acids have been added, relative to the amino acid sequence of SEQ ID NO:2, and having allergenicity of Dermatophagoides farina; and
(c) a protein comprising an amino acid sequence having 90% or higher identity with the amino acid sequence of SEQ ID NO:2, and having allergenicity of Dermatophagoides farinae.
US Pat. No. 10,457,967

IN-SITU BIOSTIMULATION OF THE HYDROLYSIS OF ORGANIC MATTER FOR OPTIMIZING THE ENERGY RECOVERY THEREFROM

1. A process for the treatment of a first, at least partially organic and at least partially solid, substrate, comprising:A. introduction of an initial volume of said first substrate to be treated into at least one hydrolysis reactor;
B. introduction of an initial volume of second substrate into at least one biostimulation reactor;
C. biostimulation of the second substrate contained in said biostimulation reactor by indigenous microorganisms and absent inoculated exogenous strains, under aerobic conditions, at a temperature of between 20° C. and 40° C., a pH of between 4 and 7, a moisture level of between 50% and 80% and a residence time of between 1 and 5 days, to ensure at least partial hydrolysis of the organic portion of said substrate and the in situ production of hydrolytic enzymes;
D. percolation of a liquid through said volume of second substrate contained in said biostimulation reactor, in order to form a first leachate enriched in hydrolytic enzymes;
E. injection of the first leachate enriched in hydrolytic enzymes into at least one hydrolysis reactor containing said first substrate to be treated; and
F. hydrolysis of the first substrate at least partially by the first enriched leachate; wherein the succession of the steps C and D define a biostimulation cycle.
US Pat. No. 10,458,993

ASSAY FOR ASSESSING CONFORMATIONAL STABILITY OF MEMBRANE PROTEIN

Heptares Therapeutics Lim...

1. An assay for assessing the conformational stability of a membrane protein, comprising:(a) providing a sample comprising a first population and a second population of a membrane protein; wherein the membrane protein in the first population is labelled with a donor label and the membrane protein in the second population is labelled with an acceptor label, or the membrane protein in the first population is labelled with an acceptor label and the membrane protein in the second population is labelled with a donor label, and wherein the populations of membrane protein are provided in a solubilized form,
(b) exposing the first and second populations of the membrane protein provided in the solubilized form to a denaturant or denaturing condition, and
(c) assessing aggregation between membrane proteins of the first and second populations by activating the donor label to permit a distance-dependent interaction with the acceptor label, which interaction produces a detectable signal.
US Pat. No. 10,456,429

USE OF PROBIOTIC MICRO-ORGANISMS AS AN AGENT THAT PROMOTES THE SYNTHESIS OF MELANIN

NESTEC S.A., Vevey (CH)

1. A non-therapeutic cosmetic method which comprises topically administering to a subject at least one probiotic Bifidobacterium longum subsp. longum micro-organism strain registered on Jan. 29, 2001 with CNCM (Paris, France) under the number I-2618, as an agent inducing skin and/or hair pigmentation, for promoting melanin synthesis thereby homogenizing the color of the skin and/or hair of said subject, wherein said Bifidobacterium longum subsp. longum CNCM I-2618 strain is in at least partially inactivated form and is presented in the form of a cell extract or lysate containing cell fragments and metabolites.
US Pat. No. 10,457,712

PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. An expression vector expressing a nucleic acid encoding a peptide consisting of the amino acid sequence of GLIDEVMVL (SEQ ID NO: 22) or FLDANGHFV (SEQ ID NO: 23).